Clinical practice guidelines for the management of adult diffuse gliomas
To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro‐Oncology of China (SNO-China) and Chinese Brain Cancer Association (CBCA) updat...
Uloženo v:
| Vydáno v: | Cancer letters Ročník 499; s. 60 - 72 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Ireland
Elsevier B.V
28.02.2021
Elsevier Limited |
| Témata: | |
| ISSN: | 0304-3835, 1872-7980, 1872-7980 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro‐Oncology of China (SNO-China) and Chinese Brain Cancer Association (CBCA) updated the clinical practice guideline. It provides recommendations for diagnostic and management decisions, and for limiting unnecessary treatments and cost. The recommendations focus on molecular and pathological diagnostics, and the main treatment modalities of surgery, radiotherapy, and chemotherapy. In this guideline, we also integrated the results of some clinical trials of immune therapies and target therapies, which we think are ongoing future directions. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China and other countries.
•The guideline provides diagnostic and management recommendations for diffuse gliomas.•The guideline focuses on molecular diagnostics, and the main treatment modalities.•The guideline includes clinical trials of immune therapies and target therapies.•The guideline should serve as an application for all medical professionals. |
|---|---|
| AbstractList | To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro‐Oncology of China (SNO-China) and Chinese Brain Cancer Association (CBCA) updated the clinical practice guideline. It provides recommendations for diagnostic and management decisions, and for limiting unnecessary treatments and cost. The recommendations focus on molecular and pathological diagnostics, and the main treatment modalities of surgery, radiotherapy, and chemotherapy. In this guideline, we also integrated the results of some clinical trials of immune therapies and target therapies, which we think are ongoing future directions. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China and other countries.
•The guideline provides diagnostic and management recommendations for diffuse gliomas.•The guideline focuses on molecular diagnostics, and the main treatment modalities.•The guideline includes clinical trials of immune therapies and target therapies.•The guideline should serve as an application for all medical professionals. To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro-Oncology of China (SNO-China) and Chinese Brain Cancer Association (CBCA) updated the clinical practice guideline. It provides recommendations for diagnostic and management decisions, and for limiting unnecessary treatments and cost. The recommendations focus on molecular and pathological diagnostics, and the main treatment modalities of surgery, radiotherapy, and chemotherapy. In this guideline, we also integrated the results of some clinical trials of immune therapies and target therapies, which we think are ongoing future directions. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China and other countries.To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro-Oncology of China (SNO-China) and Chinese Brain Cancer Association (CBCA) updated the clinical practice guideline. It provides recommendations for diagnostic and management decisions, and for limiting unnecessary treatments and cost. The recommendations focus on molecular and pathological diagnostics, and the main treatment modalities of surgery, radiotherapy, and chemotherapy. In this guideline, we also integrated the results of some clinical trials of immune therapies and target therapies, which we think are ongoing future directions. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China and other countries. To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro‐Oncology of China (SNO-China) and Chinese Brain Cancer Association (CBCA) updated the clinical practice guideline. It provides recommendations for diagnostic and management decisions, and for limiting unnecessary treatments and cost. The recommendations focus on molecular and pathological diagnostics, and the main treatment modalities of surgery, radiotherapy, and chemotherapy. In this guideline, we also integrated the results of some clinical trials of immune therapies and target therapies, which we think are ongoing future directions. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China and other countries. |
| Author | Wang, Weimin Ram, Zvi Xu, Guozheng Li, Guilin Wang, Zheng Li, Xuejun Wang, Yinyan Liu, Xianzhi Zhang, Zhiwen Liu, Xing Wang, Zhiliang Li, Lianwang Jiang, Tao Nam, Do-Hyun Li, Guanzhang Dai, Yiwu You, Gan Li, Yiming Kang, Chunsheng Yao, Kun Yang, Yuan Cai, Jinquan Wei, Xinting Sai, Ke Poon, Wai-sang Wang, Yongzhi Li, Shouwei Liu, Yuqing Yao, Yu Yang, Xuejun Dong, Jun Wang, Qixue Wang, Liang Qiu, Xiaoguang Chen, Ling Ma, Xiaodong Fan, Xing Chen, Baoshi Li, Wenbin Shan, Xia Wang, Hongjun Ma, Wenbin Mao, Qing Wang, Jiguang Fang, Shengyu Lin, Zhixiong Zhang, Chuanbao Liu, Shuai Wang, Yu Mao, Ying Lv, Shengqing Zhang, Wei Han, Lei Liu, Zhixiong Boldbaatar, Damdindorj You, Yongping Jiang, Chuanlu Chen, Lingchao Li, Shaowu Bai, Hongmin Liu, Yanwei Wu, Anhua Yang, Pei Yan, Wei Chai, Ruichao Bao, Zhaoshi Zhao, Zheng Hu, Huimin Chen, Jing |
| Author_xml | – sequence: 1 givenname: Tao surname: Jiang fullname: Jiang, Tao email: taojiang1964@163.com organization: Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China – sequence: 2 givenname: Do-Hyun surname: Nam fullname: Nam, Do-Hyun email: biovictory2@gmail.com organization: Department of Neurosurgery, Samsung Medical Center, South Korea – sequence: 3 givenname: Zvi surname: Ram fullname: Ram, Zvi email: zviram@tlvmc.gov.il organization: Department of Neurosurgery, Tel Aviv Medical Center, Israel – sequence: 4 givenname: Wai-sang orcidid: 0000-0001-5368-3480 surname: Poon fullname: Poon, Wai-sang email: poonws@surgery.cuhk.edu.hk organization: Department of Neurosurgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China – sequence: 5 givenname: Jiguang orcidid: 0000-0002-6923-4097 surname: Wang fullname: Wang, Jiguang email: jgwang@ust.hk organization: Division of Life Science, Department of Chemical and Biological Engineering, Hong Kong University of Science and Technology, Hong Kong, China – sequence: 6 givenname: Damdindorj orcidid: 0000-0002-0925-9823 surname: Boldbaatar fullname: Boldbaatar, Damdindorj email: damdindorj@mnums.edu.mn organization: Department of Physiology, School of Biomedicine, Mongolian National University of Medical Sciences, Mongolia – sequence: 7 givenname: Ying surname: Mao fullname: Mao, Ying email: maoying@fudan.edu.cn organization: Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 200040, China – sequence: 8 givenname: Wenbin surname: Ma fullname: Ma, Wenbin email: mawb2001@hotmail.com organization: Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China – sequence: 9 givenname: Qing surname: Mao fullname: Mao, Qing email: qingmao2000@163.com organization: Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, China – sequence: 10 givenname: Yongping surname: You fullname: You, Yongping email: yypl3@sohu.com organization: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China – sequence: 11 givenname: Chuanlu surname: Jiang fullname: Jiang, Chuanlu email: jcl6688@163.com organization: Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China – sequence: 12 givenname: Xuejun surname: Yang fullname: Yang, Xuejun email: ydenny@yahoo.com organization: Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300052, China – sequence: 13 givenname: Chunsheng surname: Kang fullname: Kang, Chunsheng organization: Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300052, China – sequence: 14 givenname: Xiaoguang surname: Qiu fullname: Qiu, Xiaoguang organization: Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China – sequence: 15 givenname: Wenbin surname: Li fullname: Li, Wenbin organization: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China – sequence: 16 givenname: Shaowu surname: Li fullname: Li, Shaowu organization: Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China – sequence: 17 givenname: Ling surname: Chen fullname: Chen, Ling organization: Department of Neurosurgery, Chinese PLA General Hospital, Beijing, 100853, China – sequence: 18 givenname: Xuejun surname: Li fullname: Li, Xuejun organization: Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China – sequence: 19 givenname: Zhixiong surname: Liu fullname: Liu, Zhixiong organization: Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China – sequence: 20 givenname: Weimin surname: Wang fullname: Wang, Weimin organization: Department of Neurosurgery, General Hospital of Southern Theatre Command, Guangzhou, 510010, China – sequence: 21 givenname: Hongmin surname: Bai fullname: Bai, Hongmin organization: Department of Neurosurgery, General Hospital of Southern Theatre Command, Guangzhou, 510010, China – sequence: 22 givenname: Yu surname: Yao fullname: Yao, Yu organization: Department of Physiology, School of Biomedicine, Mongolian National University of Medical Sciences, Mongolia – sequence: 23 givenname: Shouwei surname: Li fullname: Li, Shouwei organization: Department of Neurosurgery, San Bo Brain Hospital, Capital Medical University, Beijing, 100093, China – sequence: 24 givenname: Anhua surname: Wu fullname: Wu, Anhua organization: Department of Neurosurgery, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China – sequence: 25 givenname: Ke surname: Sai fullname: Sai, Ke organization: Department of Neurosurgery, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China – sequence: 26 givenname: Guilin surname: Li fullname: Li, Guilin organization: Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China – sequence: 27 givenname: Kun surname: Yao fullname: Yao, Kun organization: Department of Pathology, San Bo Brain Hospital, Capital Medical University, Beijing, 100093, China – sequence: 28 givenname: Xinting surname: Wei fullname: Wei, Xinting organization: Department of Neurosurgery, The 1st Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China – sequence: 29 givenname: Xianzhi surname: Liu fullname: Liu, Xianzhi organization: Department of Neurosurgery, The 1st Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China – sequence: 30 givenname: Zhiwen surname: Zhang fullname: Zhang, Zhiwen organization: Department of Neurosurgery, The Fourth Medical Center of PLA General Hospital, Beijing, 100048, China – sequence: 31 givenname: Yiwu surname: Dai fullname: Dai, Yiwu organization: Department of Neurosurgery, The Seventh Medical Center of PLA General Hospital, Beijing, 100700, China – sequence: 32 givenname: Shengqing surname: Lv fullname: Lv, Shengqing organization: Department of Neurosurgery, Xinqiao Hospital, Army Medical University, Chongqing, 400038, China – sequence: 33 givenname: Liang surname: Wang fullname: Wang, Liang organization: Department of Neurosurgery, Tangdu Hospital, Air Force Medical University, Xi'an, 710038, China – sequence: 34 givenname: Zhixiong surname: Lin fullname: Lin, Zhixiong organization: Department of Neurosurgery, San Bo Brain Hospital, Capital Medical University, Beijing, 100093, China – sequence: 35 givenname: Jun surname: Dong fullname: Dong, Jun organization: Department of Neurosurgery, Medical College of Soochow University, Suzhou, 215123, China – sequence: 36 givenname: Guozheng surname: Xu fullname: Xu, Guozheng organization: Department of Neurosurgery, General Hospital of Central Theatre Command, Wuhan, 430070, China – sequence: 37 givenname: Xiaodong surname: Ma fullname: Ma, Xiaodong organization: Department of Neurosurgery, Chinese PLA General Hospital, Beijing, 100853, China – sequence: 38 givenname: Wei surname: Zhang fullname: Zhang, Wei organization: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China – sequence: 39 givenname: Chuanbao surname: Zhang fullname: Zhang, Chuanbao organization: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China – sequence: 40 givenname: Baoshi surname: Chen fullname: Chen, Baoshi organization: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China – sequence: 41 givenname: Gan surname: You fullname: You, Gan organization: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China – sequence: 42 givenname: Yongzhi surname: Wang fullname: Wang, Yongzhi organization: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China – sequence: 43 givenname: Yinyan surname: Wang fullname: Wang, Yinyan organization: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China – sequence: 44 givenname: Zhaoshi surname: Bao fullname: Bao, Zhaoshi organization: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China – sequence: 45 givenname: Pei surname: Yang fullname: Yang, Pei organization: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China – sequence: 46 givenname: Xing surname: Fan fullname: Fan, Xing organization: Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China – sequence: 47 givenname: Xing surname: Liu fullname: Liu, Xing organization: Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China – sequence: 48 givenname: Zheng surname: Zhao fullname: Zhao, Zheng organization: Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China – sequence: 49 givenname: Zheng surname: Wang fullname: Wang, Zheng organization: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China – sequence: 50 givenname: Yiming surname: Li fullname: Li, Yiming organization: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China – sequence: 51 givenname: Zhiliang surname: Wang fullname: Wang, Zhiliang organization: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China – sequence: 52 givenname: Guanzhang orcidid: 0000-0002-0353-5751 surname: Li fullname: Li, Guanzhang organization: Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China – sequence: 53 givenname: Shengyu surname: Fang fullname: Fang, Shengyu organization: Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China – sequence: 54 givenname: Lianwang surname: Li fullname: Li, Lianwang organization: Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China – sequence: 55 givenname: Yanwei surname: Liu fullname: Liu, Yanwei organization: Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China – sequence: 56 givenname: Shuai surname: Liu fullname: Liu, Shuai organization: Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China – sequence: 57 givenname: Xia surname: Shan fullname: Shan, Xia organization: Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China – sequence: 58 givenname: Yuqing surname: Liu fullname: Liu, Yuqing organization: Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China – sequence: 59 givenname: Ruichao surname: Chai fullname: Chai, Ruichao organization: Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China – sequence: 60 givenname: Huimin surname: Hu fullname: Hu, Huimin organization: Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China – sequence: 61 givenname: Jing surname: Chen fullname: Chen, Jing organization: Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China – sequence: 62 givenname: Wei surname: Yan fullname: Yan, Wei organization: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China – sequence: 63 givenname: Jinquan surname: Cai fullname: Cai, Jinquan organization: Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China – sequence: 64 givenname: Hongjun surname: Wang fullname: Wang, Hongjun organization: Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China – sequence: 65 givenname: Lingchao surname: Chen fullname: Chen, Lingchao organization: Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 200040, China – sequence: 66 givenname: Yuan surname: Yang fullname: Yang, Yuan organization: Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, China – sequence: 67 givenname: Yu surname: Wang fullname: Wang, Yu organization: Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China – sequence: 68 givenname: Lei surname: Han fullname: Han, Lei organization: Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300052, China – sequence: 69 givenname: Qixue surname: Wang fullname: Wang, Qixue organization: Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300052, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33166616$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUFrGzEUhEVJaey0_yCUhVxyWVdaaXe1JQSCaZtCoJfkLLTSUyJXK7mStpB_Hxk7F198Eoy-GYY3S3TmgweELgleEUy6b5uVkt5BXjW42Ukr3OIPaEF439T9wPEZWmCKWU05bc_RMqUNxrhlffsJnVNKuq4j3QLdr531VklXbaNU2SqonmeroaiQKhNilV-gmqSXzzCBz1UwldSzy5W2xsyp4M6GSabP6KORLsGXw3uBnn7-eFzf1w9_fv1e3z3UijGaawNKl76EduPA2NhiTpUslcdO80aOHI-lb9-3SmE54IEqziU3umeMEYPZQC_Q9T53G8O_GVIWk00KnJMewpxEw9qBsoH3tKBXR-gmzNGXdoUq_5yX0EJ9PVDzOIEW22gnGV_F-40K8H0PqBhSimCEsllmG3yO0jpBsNgNIjZiP4jYDbJTyyDFzI7M7_knbLd7G5RT_rcQRVIWvAJtI6gsdLCnAm6OAtRh6L_wetr-BqeluPw |
| CitedBy_id | crossref_primary_10_1002_cam4_4603 crossref_primary_10_3389_fimmu_2022_955848 crossref_primary_10_1155_2022_8656865 crossref_primary_10_1007_s12094_022_02867_y crossref_primary_10_1016_j_jare_2025_05_032 crossref_primary_10_1186_s12967_025_06510_6 crossref_primary_10_3389_fendo_2022_943300 crossref_primary_10_1016_j_acra_2024_03_019 crossref_primary_10_1016_j_ejrad_2024_111477 crossref_primary_10_1016_j_saa_2022_121933 crossref_primary_10_1042_BSR20212378 crossref_primary_10_3389_fonc_2025_1624370 crossref_primary_10_3390_jpm11101036 crossref_primary_10_3390_jcm11195855 crossref_primary_10_1016_j_heliyon_2024_e36989 crossref_primary_10_1016_j_omtn_2021_01_033 crossref_primary_10_1038_s41598_023_32957_y crossref_primary_10_1007_s00234_022_02932_x crossref_primary_10_1158_1078_0432_CCR_23_0388 crossref_primary_10_1155_2021_4542995 crossref_primary_10_1007_s11060_024_04662_x crossref_primary_10_3390_molecules29102226 crossref_primary_10_1021_acsami_5c11509 crossref_primary_10_1002_cam4_5381 crossref_primary_10_1177_17588359241264727 crossref_primary_10_1038_s42003_023_05667_4 crossref_primary_10_3389_fneur_2022_819216 crossref_primary_10_1055_s_0042_1759712 crossref_primary_10_1007_s12672_025_03259_8 crossref_primary_10_3389_fonc_2023_1180662 crossref_primary_10_1097_CM9_0000000000003567 crossref_primary_10_1111_cas_15236 crossref_primary_10_1038_s41598_025_95693_5 crossref_primary_10_1007_s10517_023_05906_y crossref_primary_10_3390_jcm11175221 crossref_primary_10_1111_bpa_13153 crossref_primary_10_1016_j_freeradbiomed_2024_01_035 crossref_primary_10_1007_s00432_022_04049_3 crossref_primary_10_1186_s40478_023_01613_x crossref_primary_10_3389_fonc_2024_1368606 crossref_primary_10_1002_brb3_3465 crossref_primary_10_1186_s40246_024_00636_2 crossref_primary_10_3389_fphar_2021_743979 crossref_primary_10_1016_j_inat_2025_102062 crossref_primary_10_1186_s12951_024_02776_y crossref_primary_10_3389_fimmu_2021_809808 crossref_primary_10_3892_ol_2024_14326 crossref_primary_10_1016_j_gene_2024_149158 crossref_primary_10_3389_fonc_2022_956348 crossref_primary_10_1016_j_heliyon_2024_e33030 crossref_primary_10_1038_s41597_022_01823_3 crossref_primary_10_1016_j_redox_2025_103827 crossref_primary_10_1007_s12031_023_02115_0 crossref_primary_10_1016_j_jrras_2025_101589 crossref_primary_10_1016_j_canlet_2025_217541 crossref_primary_10_1038_s41417_025_00905_9 crossref_primary_10_1007_s11060_023_04292_9 crossref_primary_10_3389_fneur_2025_1493666 crossref_primary_10_1016_j_acra_2022_10_009 crossref_primary_10_1186_s12885_024_11996_2 crossref_primary_10_1016_j_acra_2024_02_009 crossref_primary_10_3390_cancers17010074 crossref_primary_10_1148_radiol_230793 crossref_primary_10_1016_j_intimp_2024_112438 crossref_primary_10_3389_fonc_2023_1214413 crossref_primary_10_1016_j_scs_2021_103215 crossref_primary_10_1016_j_cmet_2024_07_011 crossref_primary_10_1016_j_tranon_2024_101947 crossref_primary_10_3389_fgene_2022_1035368 crossref_primary_10_1016_j_canlet_2024_216834 crossref_primary_10_1038_s41417_024_00801_8 crossref_primary_10_1177_17562864221114357 crossref_primary_10_1186_s13046_023_02640_1 crossref_primary_10_3389_fonc_2023_1128278 crossref_primary_10_1227_neu_0000000000002495 crossref_primary_10_1007_s11010_023_04891_0 crossref_primary_10_1016_j_nano_2024_102737 crossref_primary_10_1002_epd2_70019 crossref_primary_10_1097_CM9_0000000000002446 crossref_primary_10_1080_15257770_2025_2551841 crossref_primary_10_1186_s13046_021_01897_8 crossref_primary_10_1038_s41419_022_05127_7 crossref_primary_10_1186_s40478_025_02036_6 crossref_primary_10_3389_fimmu_2023_1139268 crossref_primary_10_1016_j_cca_2024_117878 crossref_primary_10_1186_s12885_022_10385_x crossref_primary_10_3390_biom12121847 crossref_primary_10_1186_s13045_021_01191_2 crossref_primary_10_1016_j_ymthe_2021_07_002 crossref_primary_10_1007_s10142_023_01210_0 crossref_primary_10_1016_j_isci_2025_113346 crossref_primary_10_1186_s12885_025_14454_9 crossref_primary_10_3389_fneur_2024_1356715 crossref_primary_10_1097_JS9_0000000000002292 crossref_primary_10_1016_j_cellin_2025_100253 crossref_primary_10_1186_s41016_023_00329_0 crossref_primary_10_1097_MD_0000000000041147 crossref_primary_10_1186_s12883_021_02476_2 crossref_primary_10_3390_genes14030651 crossref_primary_10_1002_jgm_3724 crossref_primary_10_3390_cancers17183043 crossref_primary_10_3390_clinpract12050073 crossref_primary_10_3389_fcell_2021_777182 crossref_primary_10_3390_medicina61061034 crossref_primary_10_3390_jcm11164765 crossref_primary_10_3389_fimmu_2022_1089266 crossref_primary_10_7717_peerj_16691 crossref_primary_10_1007_s11864_021_00930_4 crossref_primary_10_1016_j_bspc_2022_104027 crossref_primary_10_1002_cam4_5368 crossref_primary_10_1016_j_mri_2025_110528 crossref_primary_10_3389_fonc_2024_1359778 crossref_primary_10_1038_s41419_023_05732_0 crossref_primary_10_1186_s12967_024_05489_w crossref_primary_10_1002_cnr2_70307 crossref_primary_10_1186_s13041_021_00831_5 crossref_primary_10_1007_s44174_022_00016_1 crossref_primary_10_1186_s40644_024_00754_z crossref_primary_10_1038_s41388_022_02275_0 crossref_primary_10_1016_j_ejrad_2023_111140 crossref_primary_10_2147_PGPM_S289345 crossref_primary_10_1007_s11060_025_04985_3 crossref_primary_10_3389_fonc_2022_882313 crossref_primary_10_1111_cns_13956 crossref_primary_10_3389_fneur_2022_871613 crossref_primary_10_1038_s41419_024_07010_z crossref_primary_10_1016_j_bbadis_2022_166522 crossref_primary_10_1016_j_jconrel_2024_10_024 crossref_primary_10_1186_s12893_024_02506_z crossref_primary_10_3389_fnmol_2022_1037835 crossref_primary_10_3389_fimmu_2025_1648601 crossref_primary_10_1080_01616412_2025_2497471 crossref_primary_10_1155_2022_9516808 crossref_primary_10_1016_j_ijbiomac_2025_141998 crossref_primary_10_1186_s12885_022_09984_5 crossref_primary_10_3389_fgene_2023_1027690 crossref_primary_10_1016_j_cellsig_2024_111168 crossref_primary_10_3389_fgene_2023_1085584 crossref_primary_10_1016_j_wneu_2021_05_091 crossref_primary_10_1186_s12885_023_11776_4 crossref_primary_10_1016_j_addr_2022_114536 crossref_primary_10_3389_fneur_2024_1404038 crossref_primary_10_1016_j_biopha_2022_114037 crossref_primary_10_1097_SCS_0000000000010786 crossref_primary_10_1016_j_compbiomed_2024_108958 crossref_primary_10_1186_s12951_024_02611_4 crossref_primary_10_1016_j_canlet_2023_216265 crossref_primary_10_1186_s13014_021_01878_3 crossref_primary_10_1590_0001_3765202220211075 crossref_primary_10_3389_fimmu_2022_982033 crossref_primary_10_3389_fonc_2022_814742 crossref_primary_10_3892_etm_2024_12380 crossref_primary_10_1002_cncr_34028 crossref_primary_10_3389_fimmu_2024_1488894 crossref_primary_10_3390_brainsci13091349 crossref_primary_10_2147_IJGM_S336421 crossref_primary_10_3389_fimmu_2025_1638824 crossref_primary_10_1038_s41420_024_02098_w crossref_primary_10_3389_fimmu_2021_731048 crossref_primary_10_1007_s00432_023_05082_6 crossref_primary_10_1007_s11011_024_01344_5 crossref_primary_10_1007_s00432_023_05021_5 crossref_primary_10_1186_s12964_021_00814_y crossref_primary_10_1002_jmri_28103 crossref_primary_10_1002_adhm_202300591 crossref_primary_10_1007_s44178_022_00014_9 crossref_primary_10_1038_s41467_025_56456_y crossref_primary_10_2147_JIR_S473932 crossref_primary_10_1002_mc_23911 crossref_primary_10_1007_s12017_024_08795_0 crossref_primary_10_3389_fcell_2020_615970 crossref_primary_10_1038_s41556_024_01428_5 crossref_primary_10_1016_j_canlet_2024_217154 crossref_primary_10_1016_j_net_2025_103484 crossref_primary_10_1007_s00330_023_09861_0 crossref_primary_10_1007_s12035_023_03893_9 crossref_primary_10_1080_02648725_2023_2177034 crossref_primary_10_1016_j_gene_2024_148220 crossref_primary_10_3389_fphar_2023_1191480 crossref_primary_10_1016_j_yexcr_2024_114076 crossref_primary_10_1002_advs_202503360 crossref_primary_10_1016_j_jneuroim_2023_578034 crossref_primary_10_3389_fneur_2023_1193844 crossref_primary_10_1038_s41598_024_51994_9 crossref_primary_10_1016_j_tranon_2024_102068 crossref_primary_10_1007_s00234_022_03059_9 crossref_primary_10_1016_j_eurpolymj_2024_112823 crossref_primary_10_3389_fimmu_2023_1105489 crossref_primary_10_1007_s00432_023_04894_w crossref_primary_10_1016_j_mrrev_2025_108537 crossref_primary_10_1080_01616412_2025_2480326 crossref_primary_10_1111_cns_70396 crossref_primary_10_1186_s12951_025_03406_x crossref_primary_10_1186_s12885_022_09982_7 crossref_primary_10_1007_s00415_024_12764_9 crossref_primary_10_1016_j_critrevonc_2025_104649 crossref_primary_10_1093_brain_awab340 crossref_primary_10_1016_j_jddst_2024_105721 crossref_primary_10_1002_ibra_12150 crossref_primary_10_1016_j_ijpharm_2021_120978 crossref_primary_10_3389_fmed_2023_1171819 crossref_primary_10_1007_s12672_024_01402_5 crossref_primary_10_1111_cns_14698 crossref_primary_10_1186_s41016_022_00271_7 crossref_primary_10_1016_j_knosys_2021_107692 crossref_primary_10_2147_NDT_S451300 crossref_primary_10_1080_14737140_2022_2000396 crossref_primary_10_1186_s13045_021_01124_z crossref_primary_10_1016_j_mri_2023_09_001 crossref_primary_10_3389_fonc_2022_986387 crossref_primary_10_1186_s12885_022_10491_w crossref_primary_10_1186_s12885_023_10896_1 crossref_primary_10_1097_CM9_0000000000001751 crossref_primary_10_1007_s00330_023_10212_2 crossref_primary_10_1002_cam4_5187 crossref_primary_10_1002_jmri_29561 crossref_primary_10_1016_j_cellsig_2024_111231 crossref_primary_10_1016_j_heliyon_2024_e29275 crossref_primary_10_1371_journal_pone_0319220 crossref_primary_10_3892_ol_2024_14222 crossref_primary_10_3390_genes14030580 crossref_primary_10_1038_s41419_021_04427_8 crossref_primary_10_3390_ijms22168942 crossref_primary_10_1111_cns_13817 crossref_primary_10_1007_s11060_021_03858_9 crossref_primary_10_1016_j_canlet_2023_216467 crossref_primary_10_1155_2022_9408886 crossref_primary_10_12677_WJCR_2022_122006 crossref_primary_10_1016_j_compbiomed_2022_105924 crossref_primary_10_1016_j_clineuro_2021_107015 crossref_primary_10_2174_0929867328666210827103049 crossref_primary_10_1007_s00262_021_03058_4 crossref_primary_10_1093_neuonc_noac156 crossref_primary_10_1177_09731296231216828 crossref_primary_10_1111_bpa_13198 crossref_primary_10_1016_j_canlet_2021_04_020 crossref_primary_10_1111_cns_13944 crossref_primary_10_1155_2024_6147483 crossref_primary_10_1158_2159_8290_CD_22_0196 crossref_primary_10_3389_fonc_2022_889351 crossref_primary_10_1016_j_ijbiomac_2022_12_044 crossref_primary_10_1111_jcmm_16874 crossref_primary_10_3389_fimmu_2024_1361351 crossref_primary_10_1016_j_nano_2022_102554 crossref_primary_10_1186_s12967_023_03950_w crossref_primary_10_2147_JIR_S398775 crossref_primary_10_1016_j_intimp_2021_108451 crossref_primary_10_1038_s41388_021_01878_3 |
| Cites_doi | 10.1016/S0140-6736(17)31442-3 10.1007/s00401-014-1315-x 10.1001/jamaoncol.2018.1977 10.1007/s11060-016-2332-5 10.1200/JCO.19.03327 10.1093/neuonc/noz175.064 10.1056/NEJMoa043331 10.1007/s11060-013-1103-9 10.1200/JCO.2012.43.2674 10.1212/01.wnl.0000262034.26310.a2 10.1016/S1470-2045(17)30345-5 10.1200/JCO.2017.72.7511 10.1016/S1474-4422(18)30468-X 10.1007/s11060-007-9425-0 10.1056/NEJMoa1716435 10.1038/nm.4204 10.1158/1078-0432.CCR-17-3445 10.1101/gr.165126.113 10.1200/JCO.2009.26.3541 10.1007/s00401-020-02127-9 10.1007/s10014-018-0324-1 10.1126/science.1220834 10.1093/neuonc/nox209 10.3171/2008.4.17536 10.1038/s41591-018-0339-5 10.1093/neuros/nyz441 10.1080/2162402X.2016.1196310 10.3174/ajnr.A5342 10.1016/S1470-2045(09)70025-7 10.1093/neuonc/noy032 10.3171/2011.2.JNS10998 10.1007/s00401-018-1913-0 10.1200/JCO.2008.20.7944 10.1093/neuonc/noaa121 10.1245/s10434-016-5410-1 10.1158/1078-0432.CCR-18-1140 10.1016/j.ijrobp.2014.11.012 10.1158/1078-0432.CCR-15-3153 10.1007/s11060-016-2201-2 10.3171/2017.3.JNS162383 10.1038/nm.4293 10.1038/ng.2734 10.1007/s11060-018-2985-3 10.1056/NEJMoa1308345 10.1056/NEJMoa1611977 10.2176/nmc.53.447 10.1007/s11060-017-2599-1 10.1016/S1470-2045(17)30517-X 10.1007/s00401-015-1409-0 10.1007/s00330-004-2565-0 10.20892/j.issn.2095-3941.2019.0143 10.1007/s00415-009-5156-9 10.1093/neuonc/nou097 10.1371/journal.pone.0080916 10.1007/s00432-013-1519-9 10.1007/s00401-018-1905-0 10.1212/WNL.0b013e3181e1cf3a 10.1007/s11060-010-0193-x 10.1093/neuros/nyx265 10.1038/nature10866 10.1093/neuonc/noz222 10.1038/ng.3590 10.1007/s10072-018-3407-1 10.1038/nm.4296 10.1126/science.1164382 10.1111/bpa.12367 10.1007/s00401-017-1690-1 10.1056/NEJMoa1610497 10.1007/s00701-015-2621-3 10.1200/JCO.2012.43.2229 10.1016/j.canlet.2016.01.024 10.1007/s00401-017-1781-z 10.1007/s00401-018-1826-y 10.1007/s00062-015-0496-6 10.1073/pnas.1303607110 10.1093/neuonc/noq025 10.1186/s40478-017-0449-1 10.1093/neuonc/noz126.000 10.1158/2159-8290.CD-19-1265 10.1093/neuonc/nos197 10.1038/nature07385 10.1212/WNL.54.10.1886 10.1186/s41016-020-00198-x 10.1186/s40478-017-0465-1 10.1056/NEJMoa1308573 10.1001/jama.2017.18718 10.1056/NEJMoa0808710 10.3389/fnhum.2020.00118 10.1007/s00401-018-1849-4 10.1093/neuonc/noq157 10.1007/s00401-016-1545-1 10.1007/s11060-020-03520-w 10.1093/neuonc/now002 10.1016/j.bandl.2019.104741 10.1093/nop/npv038 10.1007/s00401-019-01987-0 10.1016/S1470-2045(17)30194-8 10.1016/j.neuchi.2016.09.006 10.1056/NEJMoa065901 10.1158/1078-0432.CCR-14-2199 10.1001/jamaoncol.2019.6143 10.1016/S1470-2045(15)00088-1 10.1016/j.ccr.2012.08.024 10.1093/neuonc/nox132 10.1111/bpa.12832 10.1007/s00401-018-1808-0 10.1056/NEJMoa1407279 10.1007/s40263-019-00684-6 10.1056/NEJMoa1103782 10.1007/s11060-010-0126-8 10.1016/S1470-2045(18)30675-2 10.1016/S1470-2045(08)70125-6 10.1001/jamaoncol.2020.1024 10.1002/ana.21044 10.1038/s41591-018-0337-7 10.1093/neuonc/nox176 10.1016/j.cell.2018.09.038 10.1093/neuonc/now021 10.1200/JCO.2004.06.082 |
| ContentType | Journal Article |
| Copyright | 2020 Elsevier B.V. Copyright © 2020 Elsevier B.V. All rights reserved. 2020. Elsevier B.V. |
| Copyright_xml | – notice: 2020 Elsevier B.V. – notice: Copyright © 2020 Elsevier B.V. All rights reserved. – notice: 2020. Elsevier B.V. |
| CorporateAuthor | Society for Neuro‐Oncology of China (SNO-China) Chinese Glioma Cooperative Group (CGCG) Asian Glioma Genome Atlas (AGGA) network Chinese Glioma Genome Atlas (CGGA) Chinese Brain Cancer Association (CBCA) |
| CorporateAuthor_xml | – name: Chinese Brain Cancer Association (CBCA) – name: Asian Glioma Genome Atlas (AGGA) network – name: Society for Neuro‐Oncology of China (SNO-China) – name: Chinese Glioma Genome Atlas (CGGA) – name: Chinese Glioma Cooperative Group (CGCG) |
| DBID | AAYXX CITATION NPM 7TO 7U9 H94 K9. NAPCQ 7X8 |
| DOI | 10.1016/j.canlet.2020.10.050 |
| DatabaseName | CrossRef PubMed Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1872-7980 |
| EndPage | 72 |
| ExternalDocumentID | 33166616 10_1016_j_canlet_2020_10_050 S030438352030584X |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29B 4.4 457 4CK 4G. 5GY 5RE 5VS 6J9 6PF 7-5 71M 8FE 8FH 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABGSF ABJNI ABMAC ABMZM ABUDA ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT ADUVX AEBSH AEFWE AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFPUW AFRAH AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CS3 DU5 EBS EFJIC EFKBS EFLBG EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IH2 IHE J1W K-O KOM LK8 M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 ROL RPZ SCC SDF SDG SDP SEL SES SPCBC SSH SSU SSZ T5K Z5R ~G- ~HD 7RV 7X7 8C1 AACTN AAIAV ABLVK ABYKQ AFCTW AFKRA AFKWA AJOXV AMFUW AZQEC BBNVY BENPR DOVZS HCIFZ LCYCR M2M M2O M7P .55 .GJ 3O- 53G 9DU AAQXK AAYXX ABWVN ABXDB ACRPL ADMUD ADNMO AFFNX AFJKZ AGQPQ AGRDE AI. ASPBG AVWKF AZFZN CITATION EJD FEDTE FGOYB G-2 HED HMK HMO HVGLF HZ~ R2- SAE SEW UDS VH1 WUQ X7M ZGI AGCQF AGRNS NPM 7TO 7U9 H94 K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c443t-fecd020136b944b5083ca872b6d82ab80b383775cc0a9093c88a8fd74441f0493 |
| ISICitedReferencesCount | 292 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000604424500010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0304-3835 1872-7980 |
| IngestDate | Sun Sep 28 04:27:17 EDT 2025 Tue Oct 07 06:36:53 EDT 2025 Mon Jul 21 06:02:47 EDT 2025 Sat Nov 29 07:22:37 EST 2025 Tue Nov 18 21:07:20 EST 2025 Fri Feb 23 02:47:56 EST 2024 Tue Oct 14 19:30:14 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Immune therapy Molecular diagnostics Surgery Chemoradiation Target therapy |
| Language | English |
| License | Copyright © 2020 Elsevier B.V. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c443t-fecd020136b944b5083ca872b6d82ab80b383775cc0a9093c88a8fd74441f0493 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Instructional Material/Guideline-3 content type line 23 |
| ORCID | 0000-0002-0353-5751 0000-0001-5368-3480 0000-0002-6923-4097 0000-0002-0925-9823 |
| PMID | 33166616 |
| PQID | 2473388441 |
| PQPubID | 2031080 |
| PageCount | 13 |
| ParticipantIDs | proquest_miscellaneous_2459349873 proquest_journals_2473388441 pubmed_primary_33166616 crossref_citationtrail_10_1016_j_canlet_2020_10_050 crossref_primary_10_1016_j_canlet_2020_10_050 elsevier_sciencedirect_doi_10_1016_j_canlet_2020_10_050 elsevier_clinicalkey_doi_10_1016_j_canlet_2020_10_050 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-02-28 |
| PublicationDateYYYYMMDD | 2021-02-28 |
| PublicationDate_xml | – month: 02 year: 2021 text: 2021-02-28 day: 28 |
| PublicationDecade | 2020 |
| PublicationPlace | Ireland |
| PublicationPlace_xml | – name: Ireland – name: Clare |
| PublicationTitle | Cancer letters |
| PublicationTitleAlternate | Cancer Lett |
| PublicationYear | 2021 |
| Publisher | Elsevier B.V Elsevier Limited |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier Limited |
| References | Bagley, Desai, Linette (bib123) 2018; 20 Brat, Aldape, Colman (bib28) 2020; 139 Lizarazu, Gil-Robles, Pomposo (bib55) 2020; 202 Ellison, Hawkins, Jones (bib49) 2019; 137 Chinot, Wick, Mason (bib82) 2014; 370 Li, Wang, Cai (bib125) 2015; 10 Karpel-Massler, Nguyen, Shang (bib128) 2019; 33 Yan, Parsons, Jin (bib8) 2009; 360 Glantz, Cole, Forsyth (bib91) 2000; 54 Hu, Mu, Bao (bib44) 2018; 175 Louis, Wesseling, Aldape (bib22) 2020; 30 Bulubas, Sardesh, Traut (bib57) 2020; 14 Usery, Michael, Sills (bib90) 2010; 99 Cloughesy, Mochizuki, Orpilla (bib119) 2019; 25 Parsons, Jones, Zhang (bib127) 2008; 321 Jiang, Tang, Lin (bib6) 2011; 124 Perry (bib93) 2012; 14 Nitta, Muragaki, Maruyama (bib63) 2013; 53 Brain, Other (bib3) 2019; 18 Koriyama, Nitta, Kobayashi (bib61) 2018; 35 Di Stefano, Picca, Saragoussi (bib109) 2020 International Cancer Genome Consortium PedBrain Tumor (bib110) 2016; 22 Cairncross, Wang, Shaw (bib76) 2013; 31 Desjardins, Gromeier, Herndon (bib116) 2018; 379 Yang, Cai, Yan (bib34) 2016; 18 Yang, Wang, Peng (bib7) 2013; 113 David, Louis, Wiestler, Cavenee (bib19) 2016 Chen, Zheng, Baade (bib4) 2016; 66 Killela, Reitman, Jiao (bib33) 2013; 110 Parker, Annala, Cogdell (bib108) 2013; 123 Fang, Bai, Fan (bib53) 2020; 86 Appay, Dehais, Maurage (bib31) 2019; 21 Perry, Laperriere, O'Callaghan (bib80) 2017; 376 Zhai, Li, Jiang (bib122) 2019; 9 Lu, Hsu, Hsieh (bib60) 2018; 24 Molinaro, Hervey-Jumper, Morshed (bib72) 2020 Apr 1; 6 Majos, Tybor, Stefanczyk (bib50) 2005; 15 Spena, D'Agata, Panciani (bib52) 2013; 8 Okada, Weller, Huang (bib99) 2015; 16 Brown, Alizadeh, Starr (bib121) 2016; 375 Ding, Wang, Chen (bib64) 2018; 140 Lee, Koh, Kim (bib32) 2017; 5 Subbiah, Puzanov, Blay (bib39) 2020; 10 Kaloshi, Benouaich-Amiel, Diakite (bib16) 2007; 68 Yan, Zhang, You (bib126) 2012; 7 Stupp, Taillibert, Kanner (bib86) 2017; 318 Aoki, Nakamura, Suzuki (bib30) 2018; 20 Li, Wang, Li (bib59) 2020; 6 Shirahata, Ono, Stichel (bib48) 2018; 136 Weller, Weber, Willscher (bib9) 2015; 129 Mellinghoff, Ellingson, Touat (bib12) 2020 Oct 10; 38 Labussiere, Idbaih, Wang (bib15) 2010; 74 Weller, van den Bent, Tonn (bib95) 2017; 18 Youland, Kreofsky, Schomas (bib73) 2017; 135 Louis, Giannini, Capper (bib18) 2018; 135 Fisher, Hu, Macdonald (bib74) 2015; 91 Wiestler, Capper, Sill (bib10) 2014; 128 van den Bent, Baumert, Erridge (bib78) 2017; 390 Yordanova, Duffau (bib69) 2017; 63 Wang, Zhang, Liu (bib117) 2016; 5 Cancer Genome Atlas Research (bib100) 2008; 455 Avramescu-Murphy, Hattingen, Forster (bib56) 2017; 27 McGirt, Chaichana, Gathinji (bib70) 2009; 110 Frattini, Trifonov, Chan (bib111) 2013; 45 Bell, Zhang, Fisher (bib75) 2018; 4 Iwamoto, Lamborn, Robins (bib107) 2010; 12 Wick, Roth, Hartmann (bib17) 2016; 18 Turcan, Rohle, Goenka (bib11) 2012; 483 Louis, Wesseling, Paulus (bib46) 2018; 135 Sanai, Polley, McDermott (bib71) 2011; 115 Gilbert, Dignam, Armstrong (bib83) 2014; 370 Wick, Gorlia, Bady (bib104) 2016; 22 van den Bent, Brandes, Taphoorn (bib77) 2013; 31 Sturm, Witt, Hovestadt (bib24) 2012; 22 Piunti, Hashizume, Morgan (bib21) 2017; 23 Pace, Dirven, Koekkoek (bib94) 2017; 18 Brat, Aldape, Colman (bib29) 2018; 136 Stichel, Ebrahimi, Reuss (bib36) 2018; 136 Benit, Vecht (bib89) 2016; 3 Wang, Cazzato, Ladewig (bib112) 2016; 48 Hegi, Diserens, Gorlia (bib41) 2005; 352 Zhang, Bao, Wang (bib124) 2014; 140 Dong, Yuan, Li (bib27) 2018; 39 Wijnenga, French, Dubbink (bib65) 2018; 20 Lombardi, De Salvo, Brandes (bib105) 2019; 20 Duffau (bib68) 2016; 158 Fang, Li, Wang (bib58) 2020; 148 Patel, Bander, Venn (bib62) 2018; 82 Xie, Tan, Yang (bib26) 2019; 16 Lassman, Pugh, Wang (bib102) 2019; 21 Tan, Ashley, Lopez (bib92) 2020 Jul; 70 Pekmezci, Rice, Molinaro (bib25) 2017; 133 Mohammad, Weissmann, Leblanc (bib20) 2017; 23 Everhard, Kaloshi, Criniere (bib40) 2006; 60 Chen, Voronovich, Clark (bib47) 2014; 16 Wang, Chen, Zhou (bib5) 2016; 23 Schalper, Rodriguez-Ruiz, Diez-Valle (bib120) 2019; 25 Jiang, Mao, Ma (bib2) 2016; 375 Louis, Perry, Reifenberger (bib1) 2016; 131 Eckel-Passow, Lachance, Molinaro (bib14) 2015; 372 Zacher, Kaulich, Stepanow (bib13) 2017; 27 Di Stefano, Fucci, Frattini (bib42) 2015; 21 Wijnenga, Dubbink, French (bib35) 2017; 134 Talacchi, Turazzi, Locatelli (bib51) 2010; 100 Fang, Liang, Qian (bib54) 2017; 38 Singh, Chan, Zoppoli (bib43) 2012; 337 Bradley, Sherwood, Donovan (bib87) 2007; 85 Stupp, Hegi, Mason (bib79) 2009; 10 Wen, Chang, Van den Bent (bib96) 2017; 35 Reardon, Desjardins, Vredenburgh (bib37) 2020; 26 Kalpathy-Cramer, Chandra, Da (bib106) 2017; 131 Clarke, Iwamoto, Sul (bib81) 2009; 27 Kawaguchi, Sonoda, Shibahara (bib66) 2016; 129 Sampson, Aldape, Archer (bib114) 2011; 13 Wheeler, Manzanera, Bell (bib115) 2016; 18 Brandsma, Stalpers, Taal (bib97) 2008; 9 Van Den Bent, Eoli, Sepulveda (bib101) 2020; 22 Reardon, Brandes, Omuro (bib118) 2020 Jul 1; 6 Bao, Chen, Yang (bib45) 2014; 24 Keime-Guibert, Chinot, Taillandier (bib84) 2007; 356 Haque, Varlet, Puntonet (bib23) 2017; 5 Wen, Macdonald, Reardon (bib98) 2010; 28 Weller, Butowski, Tran (bib113) 2017; 18 Chinnaiyan, Won, Wen (bib103) 2018; 20 Chapman, Hauschild, Robert (bib38) 2011; 364 Fujii, Muragaki, Maruyama (bib67) 2018; 129 Roa, Brasher, Bauman (bib85) 2004; 22 van Breemen, Rijsman, Taphoorn (bib88) 2009; 256 Chen (10.1016/j.canlet.2020.10.050_bib47) 2014; 16 Reardon (10.1016/j.canlet.2020.10.050_bib37) 2020; 26 Brandsma (10.1016/j.canlet.2020.10.050_bib97) 2008; 9 Wick (10.1016/j.canlet.2020.10.050_bib17) 2016; 18 Karpel-Massler (10.1016/j.canlet.2020.10.050_bib128) 2019; 33 Turcan (10.1016/j.canlet.2020.10.050_bib11) 2012; 483 Mellinghoff (10.1016/j.canlet.2020.10.050_bib12) 2020; 38 Weller (10.1016/j.canlet.2020.10.050_bib9) 2015; 129 Kaloshi (10.1016/j.canlet.2020.10.050_bib16) 2007; 68 Wen (10.1016/j.canlet.2020.10.050_bib98) 2010; 28 Stichel (10.1016/j.canlet.2020.10.050_bib36) 2018; 136 Glantz (10.1016/j.canlet.2020.10.050_bib91) 2000; 54 Piunti (10.1016/j.canlet.2020.10.050_bib21) 2017; 23 Okada (10.1016/j.canlet.2020.10.050_bib99) 2015; 16 Fujii (10.1016/j.canlet.2020.10.050_bib67) 2018; 129 Brown (10.1016/j.canlet.2020.10.050_bib121) 2016; 375 Avramescu-Murphy (10.1016/j.canlet.2020.10.050_bib56) 2017; 27 Yang (10.1016/j.canlet.2020.10.050_bib7) 2013; 113 Chinnaiyan (10.1016/j.canlet.2020.10.050_bib103) 2018; 20 Lizarazu (10.1016/j.canlet.2020.10.050_bib55) 2020; 202 Aoki (10.1016/j.canlet.2020.10.050_bib30) 2018; 20 Brat (10.1016/j.canlet.2020.10.050_bib28) 2020; 139 Talacchi (10.1016/j.canlet.2020.10.050_bib51) 2010; 100 Li (10.1016/j.canlet.2020.10.050_bib59) 2020; 6 McGirt (10.1016/j.canlet.2020.10.050_bib70) 2009; 110 Wick (10.1016/j.canlet.2020.10.050_bib104) 2016; 22 Haque (10.1016/j.canlet.2020.10.050_bib23) 2017; 5 Bagley (10.1016/j.canlet.2020.10.050_bib123) 2018; 20 Chinot (10.1016/j.canlet.2020.10.050_bib82) 2014; 370 Kawaguchi (10.1016/j.canlet.2020.10.050_bib66) 2016; 129 Benit (10.1016/j.canlet.2020.10.050_bib89) 2016; 3 Molinaro (10.1016/j.canlet.2020.10.050_bib72) 2020; 6 Youland (10.1016/j.canlet.2020.10.050_bib73) 2017; 135 Stupp (10.1016/j.canlet.2020.10.050_bib86) 2017; 318 Desjardins (10.1016/j.canlet.2020.10.050_bib116) 2018; 379 Fisher (10.1016/j.canlet.2020.10.050_bib74) 2015; 91 Chen (10.1016/j.canlet.2020.10.050_bib4) 2016; 66 Bulubas (10.1016/j.canlet.2020.10.050_bib57) 2020; 14 Zhang (10.1016/j.canlet.2020.10.050_bib124) 2014; 140 Di Stefano (10.1016/j.canlet.2020.10.050_bib42) 2015; 21 Koriyama (10.1016/j.canlet.2020.10.050_bib61) 2018; 35 Brat (10.1016/j.canlet.2020.10.050_bib29) 2018; 136 Fang (10.1016/j.canlet.2020.10.050_bib58) 2020; 148 Lombardi (10.1016/j.canlet.2020.10.050_bib105) 2019; 20 Hegi (10.1016/j.canlet.2020.10.050_bib41) 2005; 352 Bell (10.1016/j.canlet.2020.10.050_bib75) 2018; 4 Kalpathy-Cramer (10.1016/j.canlet.2020.10.050_bib106) 2017; 131 Weller (10.1016/j.canlet.2020.10.050_bib113) 2017; 18 Weller (10.1016/j.canlet.2020.10.050_bib95) 2017; 18 Yordanova (10.1016/j.canlet.2020.10.050_bib69) 2017; 63 Perry (10.1016/j.canlet.2020.10.050_bib93) 2012; 14 Everhard (10.1016/j.canlet.2020.10.050_bib40) 2006; 60 David (10.1016/j.canlet.2020.10.050_bib19) 2016 Louis (10.1016/j.canlet.2020.10.050_bib46) 2018; 135 Keime-Guibert (10.1016/j.canlet.2020.10.050_bib84) 2007; 356 International Cancer Genome Consortium PedBrain Tumor (10.1016/j.canlet.2020.10.050_bib110) 2016; 22 Wang (10.1016/j.canlet.2020.10.050_bib117) 2016; 5 Brain (10.1016/j.canlet.2020.10.050_bib3) 2019; 18 Xie (10.1016/j.canlet.2020.10.050_bib26) 2019; 16 Sanai (10.1016/j.canlet.2020.10.050_bib71) 2011; 115 Clarke (10.1016/j.canlet.2020.10.050_bib81) 2009; 27 Yan (10.1016/j.canlet.2020.10.050_bib8) 2009; 360 Ding (10.1016/j.canlet.2020.10.050_bib64) 2018; 140 Duffau (10.1016/j.canlet.2020.10.050_bib68) 2016; 158 Wijnenga (10.1016/j.canlet.2020.10.050_bib65) 2018; 20 van den Bent (10.1016/j.canlet.2020.10.050_bib77) 2013; 31 Louis (10.1016/j.canlet.2020.10.050_bib18) 2018; 135 Van Den Bent (10.1016/j.canlet.2020.10.050_bib101) 2020; 22 Singh (10.1016/j.canlet.2020.10.050_bib43) 2012; 337 Lu (10.1016/j.canlet.2020.10.050_bib60) 2018; 24 Jiang (10.1016/j.canlet.2020.10.050_bib6) 2011; 124 Stupp (10.1016/j.canlet.2020.10.050_bib79) 2009; 10 Sturm (10.1016/j.canlet.2020.10.050_bib24) 2012; 22 Parsons (10.1016/j.canlet.2020.10.050_bib127) 2008; 321 Jiang (10.1016/j.canlet.2020.10.050_bib2) 2016; 375 Spena (10.1016/j.canlet.2020.10.050_bib52) 2013; 8 Zacher (10.1016/j.canlet.2020.10.050_bib13) 2017; 27 Eckel-Passow (10.1016/j.canlet.2020.10.050_bib14) 2015; 372 Tan (10.1016/j.canlet.2020.10.050_bib92) 2020; 70 Killela (10.1016/j.canlet.2020.10.050_bib33) 2013; 110 Fang (10.1016/j.canlet.2020.10.050_bib53) 2020; 86 Sampson (10.1016/j.canlet.2020.10.050_bib114) 2011; 13 Wheeler (10.1016/j.canlet.2020.10.050_bib115) 2016; 18 Wen (10.1016/j.canlet.2020.10.050_bib96) 2017; 35 Cancer Genome Atlas Research (10.1016/j.canlet.2020.10.050_bib100) 2008; 455 Nitta (10.1016/j.canlet.2020.10.050_bib63) 2013; 53 Cairncross (10.1016/j.canlet.2020.10.050_bib76) 2013; 31 Lee (10.1016/j.canlet.2020.10.050_bib32) 2017; 5 Schalper (10.1016/j.canlet.2020.10.050_bib120) 2019; 25 Perry (10.1016/j.canlet.2020.10.050_bib80) 2017; 376 Mohammad (10.1016/j.canlet.2020.10.050_bib20) 2017; 23 Bao (10.1016/j.canlet.2020.10.050_bib45) 2014; 24 Zhai (10.1016/j.canlet.2020.10.050_bib122) 2019; 9 Yan (10.1016/j.canlet.2020.10.050_bib126) 2012; 7 Gilbert (10.1016/j.canlet.2020.10.050_bib83) 2014; 370 Dong (10.1016/j.canlet.2020.10.050_bib27) 2018; 39 Wang (10.1016/j.canlet.2020.10.050_bib112) 2016; 48 Iwamoto (10.1016/j.canlet.2020.10.050_bib107) 2010; 12 Reardon (10.1016/j.canlet.2020.10.050_bib118) 2020; 6 Majos (10.1016/j.canlet.2020.10.050_bib50) 2005; 15 Louis (10.1016/j.canlet.2020.10.050_bib1) 2016; 131 Appay (10.1016/j.canlet.2020.10.050_bib31) 2019; 21 Li (10.1016/j.canlet.2020.10.050_bib125) 2015; 10 Yang (10.1016/j.canlet.2020.10.050_bib34) 2016; 18 Ellison (10.1016/j.canlet.2020.10.050_bib49) 2019; 137 Patel (10.1016/j.canlet.2020.10.050_bib62) 2018; 82 Pekmezci (10.1016/j.canlet.2020.10.050_bib25) 2017; 133 Wijnenga (10.1016/j.canlet.2020.10.050_bib35) 2017; 134 Frattini (10.1016/j.canlet.2020.10.050_bib111) 2013; 45 Pace (10.1016/j.canlet.2020.10.050_bib94) 2017; 18 Parker (10.1016/j.canlet.2020.10.050_bib108) 2013; 123 Chapman (10.1016/j.canlet.2020.10.050_bib38) 2011; 364 Cloughesy (10.1016/j.canlet.2020.10.050_bib119) 2019; 25 Wiestler (10.1016/j.canlet.2020.10.050_bib10) 2014; 128 Hu (10.1016/j.canlet.2020.10.050_bib44) 2018; 175 Lassman (10.1016/j.canlet.2020.10.050_bib102) 2019; 21 Louis (10.1016/j.canlet.2020.10.050_bib22) 2020; 30 Usery (10.1016/j.canlet.2020.10.050_bib90) 2010; 99 Shirahata (10.1016/j.canlet.2020.10.050_bib48) 2018; 136 van Breemen (10.1016/j.canlet.2020.10.050_bib88) 2009; 256 Roa (10.1016/j.canlet.2020.10.050_bib85) 2004; 22 Bradley (10.1016/j.canlet.2020.10.050_bib87) 2007; 85 Di Stefano (10.1016/j.canlet.2020.10.050_bib109) 2020 Subbiah (10.1016/j.canlet.2020.10.050_bib39) 2020; 10 Wang (10.1016/j.canlet.2020.10.050_bib5) 2016; 23 Fang (10.1016/j.canlet.2020.10.050_bib54) 2017; 38 Labussiere (10.1016/j.canlet.2020.10.050_bib15) 2010; 74 van den Bent (10.1016/j.canlet.2020.10.050_bib78) 2017; 390 |
| References_xml | – volume: 35 start-page: 2439 year: 2017 end-page: 2449 ident: bib96 article-title: Response assessment in neuro-oncology clinical trials publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology – volume: 39 start-page: 1191 year: 2018 end-page: 1201 ident: bib27 article-title: The clinicopathological and prognostic significance of TP53 alteration in K27M mutated gliomas: an individual-participant data meta-analysis publication-title: Neurol. Sci. – volume: 13 start-page: 324 year: 2011 end-page: 333 ident: bib114 article-title: Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma publication-title: Neuro Oncol. – volume: 128 start-page: 561 year: 2014 end-page: 571 ident: bib10 article-title: Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma publication-title: Acta Neuropathol. – volume: 91 start-page: 497 year: 2015 end-page: 504 ident: bib74 article-title: Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424 publication-title: Int. J. Radiat. Oncol. Biol. Phys. – volume: 23 start-page: 493 year: 2017 end-page: 500 ident: bib21 article-title: Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas publication-title: Nat. Med. – volume: 364 start-page: 2507 year: 2011 end-page: 2516 ident: bib38 article-title: Improved survival with vemurafenib in melanoma with BRAF V600E mutation publication-title: N. Engl. J. Med. – volume: 115 start-page: 3 year: 2011 end-page: 8 ident: bib71 article-title: An extent of resection threshold for newly diagnosed glioblastomas publication-title: J. Neurosurg. – volume: 99 start-page: 251 year: 2010 end-page: 260 ident: bib90 article-title: A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures publication-title: Journal of neuro-oncology – volume: 5 start-page: 62 year: 2017 ident: bib32 article-title: The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas publication-title: Acta Neuropathol Commun – volume: 5 start-page: 45 year: 2017 ident: bib23 article-title: Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours publication-title: Acta Neuropathol Commun – volume: 137 start-page: 683 year: 2019 end-page: 687 ident: bib49 article-title: cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation publication-title: Acta Neuropathol. – volume: 136 start-page: 805 year: 2018 end-page: 810 ident: bib29 article-title: cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV publication-title: Acta Neuropathol. – volume: 18 start-page: 1373 year: 2017 end-page: 1385 ident: bib113 article-title: Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial publication-title: Lancet Oncol. – volume: 20 start-page: 110 year: 2019 end-page: 119 ident: bib105 article-title: Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial publication-title: Lancet Oncol. – volume: 376 start-page: 1027 year: 2017 end-page: 1037 ident: bib80 article-title: Short-course radiation plus temozolomide in elderly patients with glioblastoma publication-title: N. Engl. J. Med. – volume: 10 year: 2015 ident: bib125 article-title: Isocitrate dehydrogenase 1 gene mutation is associated with prognosis in clinical low-grade gliomas publication-title: PloS One – volume: 113 start-page: 259 year: 2013 end-page: 266 ident: bib7 article-title: Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution publication-title: Journal of neuro-oncology – volume: 16 start-page: 784 year: 2019 end-page: 796 ident: bib26 article-title: Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis publication-title: Cancer Biol Med – volume: 140 start-page: 45 year: 2014 end-page: 51 ident: bib124 article-title: Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China publication-title: J. Canc. Res. Clin. Oncol. – volume: 6 start-page: 18 year: 2020 ident: bib59 article-title: Role of molecular biomarkers in glioma resection: a systematic review publication-title: Chinese Neurosurgical Journal – volume: 27 start-page: 3861 year: 2009 end-page: 3867 ident: bib81 article-title: Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology – volume: 20 start-page: 1429 year: 2018 end-page: 1438 ident: bib123 article-title: CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges publication-title: Neuro Oncol. – volume: 18 start-page: 1099 year: 2016 end-page: 1108 ident: bib34 article-title: Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas publication-title: Neuro Oncol. – volume: 60 start-page: 740 year: 2006 end-page: 743 ident: bib40 article-title: MGMT methylation: a marker of response to temozolomide in low-grade gliomas publication-title: Ann. Neurol. – volume: 16 start-page: 1478 year: 2014 end-page: 1483 ident: bib47 article-title: Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma publication-title: Neuro Oncol. – volume: 33 start-page: 1155 year: 2019 end-page: 1166 ident: bib128 article-title: Novel IDH1-targeted glioma therapies publication-title: CNS Drugs – volume: 110 start-page: 156 year: 2009 end-page: 162 ident: bib70 article-title: Independent association of extent of resection with survival in patients with malignant brain astrocytoma publication-title: J. Neurosurg. – volume: 53 start-page: 447 year: 2013 end-page: 454 ident: bib63 article-title: Updated therapeutic strategy for adult low-grade glioma stratified by resection and tumor subtype publication-title: Neurol. Med.-Chir. – volume: 18 start-page: e330 year: 2017 end-page: e340 ident: bib94 article-title: European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma publication-title: Lancet Oncol. – volume: 31 start-page: 344 year: 2013 end-page: 350 ident: bib77 article-title: Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951 publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology – volume: 22 start-page: 425 year: 2012 end-page: 437 ident: bib24 article-title: Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma publication-title: Canc. Cell – volume: 48 start-page: 768 year: 2016 end-page: 776 ident: bib112 article-title: Clonal evolution of glioblastoma under therapy publication-title: Nat. Genet. – volume: 63 start-page: 243 year: 2017 end-page: 249 ident: bib69 article-title: Supratotal resection of diffuse gliomas - an overview of its multifaceted implications publication-title: Neurochirurgie – volume: 370 start-page: 709 year: 2014 end-page: 722 ident: bib82 article-title: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma publication-title: N. Engl. J. Med. – volume: 20 start-page: 666 year: 2018 end-page: 673 ident: bib103 article-title: A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913 publication-title: Neuro Oncol. – volume: 135 start-page: 535 year: 2017 end-page: 543 ident: bib73 article-title: The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma publication-title: Journal of neuro-oncology – volume: 18 start-page: 1529 year: 2016 end-page: 1537 ident: bib17 article-title: Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide publication-title: Neuro Oncol. – volume: 24 start-page: 1765 year: 2014 end-page: 1773 ident: bib45 article-title: RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas publication-title: Genome Res. – volume: 158 start-page: 51 year: 2016 end-page: 58 ident: bib68 article-title: Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up publication-title: Acta Neurochir. – volume: 337 start-page: 1231 year: 2012 end-page: 1235 ident: bib43 article-title: Transforming fusions of FGFR and TACC genes in human glioblastoma publication-title: Science – volume: 21 start-page: 3307 year: 2015 end-page: 3317 ident: bib42 article-title: Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma publication-title: Clin. Canc. Res. : an official journal of the American Association for Cancer Research – volume: 22 start-page: 1583 year: 2004 end-page: 1588 ident: bib85 article-title: Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology – volume: 3 start-page: 245 year: 2016 end-page: 260 ident: bib89 article-title: Seizures and cancer: drug interactions of anticonvulsants with chemotherapeutic agents, tyrosine kinase inhibitors and glucocorticoids publication-title: Neuro-oncology practice – volume: 375 start-page: 263 year: 2016 end-page: 273 ident: bib2 article-title: CGCG clinical practice guidelines for the management of adult diffuse gliomas publication-title: Canc. Lett. – volume: 110 start-page: 6021 year: 2013 end-page: 6026 ident: bib33 article-title: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal publication-title: Proc. Natl. Acad. Sci. U. S. A. – year: 2020 ident: bib109 article-title: Clinical, molecular and radiomic profile of gliomas with FGFR3-TACC3 fusions publication-title: Neuro Oncol. – volume: 7 year: 2012 ident: bib126 article-title: Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China publication-title: PloS One – volume: 23 start-page: 483 year: 2017 end-page: 492 ident: bib20 article-title: EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas publication-title: Nat. Med. – volume: 321 start-page: 1807 year: 2008 end-page: 1812 ident: bib127 article-title: An integrated genomic analysis of human glioblastoma multiforme publication-title: Science – volume: 356 start-page: 1527 year: 2007 end-page: 1535 ident: bib84 article-title: Radiotherapy for glioblastoma in the elderly publication-title: N. Engl. J. Med. – volume: 390 start-page: 1645 year: 2017 end-page: 1653 ident: bib78 article-title: Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study publication-title: Lancet – volume: 379 start-page: 150 year: 2018 end-page: 161 ident: bib116 article-title: Recurrent glioblastoma treated with recombinant poliovirus publication-title: N. Engl. J. Med. – volume: 22 start-page: 684 year: 2020 end-page: 693 ident: bib101 article-title: INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma publication-title: Neuro Oncol. – volume: 136 start-page: 793 year: 2018 end-page: 803 ident: bib36 article-title: Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma publication-title: Acta Neuropathol. – volume: 129 start-page: 505 year: 2016 end-page: 514 ident: bib66 article-title: Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion publication-title: Journal of neuro-oncology – volume: 124 start-page: 2578 year: 2011 end-page: 2583 ident: bib6 article-title: Prevalence estimates for primary brain tumors in China: a multi-center cross-sectional study publication-title: Chin Med J (Engl). – volume: 20 start-page: 103 year: 2018 end-page: 112 ident: bib65 article-title: The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis publication-title: Neuro Oncol. – volume: 129 start-page: 679 year: 2015 end-page: 693 ident: bib9 article-title: Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups publication-title: Acta Neuropathol. – volume: 175 start-page: 1665 year: 2018 end-page: 1678 e1618 ident: bib44 article-title: Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor publication-title: Cell – volume: 54 start-page: 1886 year: 2000 end-page: 1893 ident: bib91 article-title: Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology publication-title: Neurology – volume: 28 start-page: 1963 year: 2010 end-page: 1972 ident: bib98 article-title: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology – volume: 372 start-page: 2499 year: 2015 end-page: 2508 ident: bib14 article-title: Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors publication-title: N. Engl. J. Med. – volume: 30 start-page: 844 year: 2020 end-page: 856 ident: bib22 article-title: cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading publication-title: Brain Pathol. – volume: 352 start-page: 997 year: 2005 end-page: 1003 ident: bib41 article-title: MGMT gene silencing and benefit from temozolomide in glioblastoma publication-title: N. Engl. J. Med. – volume: 21 year: 2019 ident: bib102 article-title: ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM) publication-title: Neuro Oncol. – volume: 133 start-page: 1001 year: 2017 end-page: 1016 ident: bib25 article-title: Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT publication-title: Acta Neuropathol. – volume: 10 start-page: 657 year: 2020 end-page: 663 ident: bib39 article-title: Pan-cancer efficacy of vemurafenib in BRAF (V600)-mutant non-melanoma cancers publication-title: Cancer Discov – volume: 70 start-page: 299 year: 2020 Jul end-page: 312 ident: bib92 article-title: Management of glioblastoma: state of the art and future directions publication-title: CA Cancer J Clin. – volume: 18 start-page: e315 year: 2017 end-page: e329 ident: bib95 article-title: European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas publication-title: Lancet Oncol. – volume: 360 start-page: 765 year: 2009 end-page: 773 ident: bib8 article-title: IDH1 and IDH2 mutations in gliomas publication-title: N. Engl. J. Med. – volume: 14 start-page: 118 year: 2020 ident: bib57 article-title: Motor cortical network plasticity in patients with recurrent brain tumors publication-title: Front. Hum. Neurosci. – volume: 25 start-page: 477 year: 2019 end-page: 486 ident: bib119 article-title: Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma publication-title: Nat. Med. – volume: 20 start-page: 66 year: 2018 end-page: 77 ident: bib30 article-title: Prognostic relevance of genetic alterations in diffuse lower-grade gliomas publication-title: Neuro Oncol. – volume: 148 start-page: 317 year: 2020 end-page: 325 ident: bib58 article-title: Awake craniotomy for gliomas involving motor-related areas: classification and function recovery publication-title: Journal of neuro-oncology – volume: 5 year: 2016 ident: bib117 article-title: Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma publication-title: OncoImmunology – volume: 26 start-page: 1586 year: 2020 end-page: 1594 ident: bib37 article-title: Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial publication-title: Clin. Canc. Res. : an official journal of the American Association for Cancer Research – volume: 9 start-page: 453 year: 2008 end-page: 461 ident: bib97 article-title: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas publication-title: Lancet Oncol. – volume: 45 start-page: 1141 year: 2013 end-page: 1149 ident: bib111 article-title: The integrated landscape of driver genomic alterations in glioblastoma publication-title: Nat. Genet. – volume: 27 start-page: 146 year: 2017 end-page: 159 ident: bib13 article-title: Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene Panel publication-title: Brain Pathol. – volume: 16 start-page: e534 year: 2015 end-page: e542 ident: bib99 article-title: Immunotherapy response assessment in neuro-oncology: a report of the RANO working group publication-title: Lancet Oncol. – volume: 370 start-page: 699 year: 2014 end-page: 708 ident: bib83 article-title: A randomized trial of bevacizumab for newly diagnosed glioblastoma publication-title: N. Engl. J. Med. – year: 2016 ident: bib19 publication-title: WHO Classification of Tumours of the Central Nervous System – volume: 134 start-page: 957 year: 2017 end-page: 959 ident: bib35 article-title: Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification publication-title: Acta Neuropathol. – volume: 100 start-page: 417 year: 2010 end-page: 426 ident: bib51 article-title: Surgical treatment of high-grade gliomas in motor areas. The impact of different supportive technologies: a 171-patient series publication-title: Journal of neuro-oncology – volume: 139 start-page: 603 year: 2020 end-page: 608 ident: bib28 article-title: cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas publication-title: Acta Neuropathol. – volume: 85 start-page: 329 year: 2007 end-page: 338 ident: bib87 article-title: I could lose everything: understanding the cost of a brain tumor publication-title: Journal of neuro-oncology – volume: 14 start-page: iv73 year: 2012 end-page: 80 ident: bib93 article-title: Thromboembolic disease in patients with high-grade glioma publication-title: Neuro Oncol. – volume: 140 start-page: 591 year: 2018 end-page: 603 ident: bib64 article-title: The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study publication-title: Journal of neuro-oncology – volume: 31 start-page: 337 year: 2013 end-page: 343 ident: bib76 article-title: Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402 publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology – volume: 15 start-page: 1148 year: 2005 end-page: 1158 ident: bib50 article-title: Cortical mapping by functional magnetic resonance imaging in patients with brain tumors publication-title: Eur. Radiol. – volume: 123 start-page: 855 year: 2013 end-page: 865 ident: bib108 article-title: The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma publication-title: J. Clin. Invest. – volume: 22 start-page: 1314 year: 2016 end-page: 1320 ident: bib110 article-title: Recurrent MET fusion genes represent a drug target in pediatric glioblastoma publication-title: Nat. Med. – volume: 18 start-page: 1137 year: 2016 end-page: 1145 ident: bib115 article-title: Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma publication-title: Neuro Oncol. – volume: 38 start-page: 3398 year: 2020 Oct 10 end-page: 3406 ident: bib12 article-title: Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma publication-title: J Clin Oncol. – volume: 318 start-page: 2306 year: 2017 end-page: 2316 ident: bib86 article-title: Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial publication-title: Jama – volume: 23 start-page: 946 year: 2016 end-page: 953 ident: bib5 article-title: Statistical report of central nervous system tumors histologically diagnosed in the sichuan province of China from 2008 to 2013: a west China glioma center report publication-title: Ann. Surg Oncol. – volume: 82 start-page: 808 year: 2018 end-page: 814 ident: bib62 article-title: The role of extent of resection in IDH1 wild-type or mutant low-grade gliomas publication-title: Neurosurgery – volume: 131 start-page: 803 year: 2016 end-page: 820 ident: bib1 article-title: The 2016 World Health organization classification of tumors of the central nervous system: a summary publication-title: Acta Neuropathol. – volume: 135 start-page: 481 year: 2018 end-page: 484 ident: bib46 article-title: cIMPACT-NOW update 1: not otherwise specified (NOS) and not elsewhere classified (NEC) publication-title: Acta Neuropathol. – volume: 27 start-page: 299 year: 2017 end-page: 309 ident: bib56 article-title: Post-surgical language reorganization occurs in tumors of the dominant and non-dominant hemisphere publication-title: Clin. Neuroradiol. – volume: 35 start-page: 159 year: 2018 end-page: 167 ident: bib61 article-title: A surgical strategy for lower grade gliomas using intraoperative molecular diagnosis publication-title: Brain Tumor Pathol. – volume: 4 start-page: 1405 year: 2018 end-page: 1409 ident: bib75 article-title: Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG oncology/RTOG 0424 trial publication-title: JAMA Oncol – volume: 6 start-page: 1003 year: 2020 Jul 1 end-page: 1010 ident: bib118 article-title: Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial publication-title: JAMA Oncol. – volume: 483 start-page: 479 year: 2012 end-page: 483 ident: bib11 article-title: IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype publication-title: Nature – volume: 10 start-page: 459 year: 2009 end-page: 466 ident: bib79 article-title: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial publication-title: Lancet Oncol. – volume: 136 start-page: 153 year: 2018 end-page: 166 ident: bib48 article-title: Novel, improved grading system(s) for IDH-mutant astrocytic gliomas publication-title: Acta Neuropathol. – volume: 131 start-page: 603 year: 2017 end-page: 610 ident: bib106 article-title: Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma publication-title: Journal of neuro-oncology – volume: 68 start-page: 1831 year: 2007 end-page: 1836 ident: bib16 article-title: Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome publication-title: Neurology – volume: 6 start-page: 495 year: 2020 Apr 1 end-page: 503 ident: bib72 article-title: Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma publication-title: JAMA Oncol – volume: 12 start-page: 855 year: 2010 end-page: 861 ident: bib107 article-title: Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02) publication-title: Neuro Oncol. – volume: 9 start-page: 2554 year: 2019 end-page: 2566 ident: bib122 article-title: CAR-armed cell therapy for gliomas publication-title: American journal of cancer research – volume: 256 start-page: 1519 year: 2009 end-page: 1526 ident: bib88 article-title: Efficacy of anti-epileptic drugs in patients with gliomas and seizures publication-title: J. Neurol. – volume: 202 start-page: 104741 year: 2020 ident: bib55 article-title: Spatiotemporal dynamics of postoperative functional plasticity in patients with brain tumors in language areas publication-title: Brain Lang. – volume: 25 start-page: 470 year: 2019 end-page: 476 ident: bib120 article-title: Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma publication-title: Nat. Med. – volume: 455 start-page: 1061 year: 2008 end-page: 1068 ident: bib100 article-title: Comprehensive genomic characterization defines human glioblastoma genes and core pathways publication-title: Nature – volume: 24 start-page: 4429 year: 2018 end-page: 4436 ident: bib60 article-title: Machine learning-based radiomics for molecular subtyping of gliomas publication-title: Clin. Canc. Res. : an official journal of the American Association for Cancer Research – volume: 22 start-page: 4797 year: 2016 end-page: 4806 ident: bib104 article-title: Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082) publication-title: Clin. Canc. Res. : an official journal of the American Association for Cancer Research – volume: 86 start-page: E124 year: 2020 end-page: E132 ident: bib53 article-title: A novel sequence: ZOOMit-blood oxygen level-dependent for motor-cortex localization publication-title: Neurosurgery – volume: 135 start-page: 639 year: 2018 end-page: 642 ident: bib18 article-title: cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant publication-title: Acta Neuropathol. – volume: 74 start-page: 1886 year: 2010 end-page: 1890 ident: bib15 article-title: All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 publication-title: Neurology – volume: 38 start-page: 1990 year: 2017 end-page: 1997 ident: bib54 article-title: Anatomic location of tumor predicts the accuracy of motor function localization in diffuse lower-grade gliomas involving the hand knob area publication-title: AJNR Am J Neuroradiol – volume: 129 start-page: 1 year: 2018 end-page: 9 ident: bib67 article-title: Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI publication-title: J. Neurosurg. – volume: 66 start-page: 115 year: 2016 end-page: 132 ident: bib4 article-title: Cancer statistics in China, 2015 publication-title: Ca - Cancer J. Clin. – volume: 8 year: 2013 ident: bib52 article-title: Supratentorial gliomas in eloquent areas: which parameters can predict functional outcome and extent of resection? publication-title: PloS One – volume: 21 start-page: 1519 year: 2019 end-page: 1528 ident: bib31 article-title: CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas publication-title: Neuro Oncol. – volume: 18 start-page: 376 year: 2019 end-page: 393 ident: bib3 article-title: Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 publication-title: Lancet Neurol. – volume: 375 start-page: 2561 year: 2016 end-page: 2569 ident: bib121 article-title: Regression of glioblastoma after chimeric antigen receptor T-cell therapy publication-title: N. Engl. J. Med. – volume: 390 start-page: 1645 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib78 article-title: Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study publication-title: Lancet doi: 10.1016/S0140-6736(17)31442-3 – volume: 128 start-page: 561 year: 2014 ident: 10.1016/j.canlet.2020.10.050_bib10 article-title: Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma publication-title: Acta Neuropathol. doi: 10.1007/s00401-014-1315-x – volume: 4 start-page: 1405 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib75 article-title: Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG oncology/RTOG 0424 trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2018.1977 – volume: 131 start-page: 603 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib106 article-title: Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma publication-title: Journal of neuro-oncology doi: 10.1007/s11060-016-2332-5 – volume: 38 start-page: 3398 issue: 29 year: 2020 ident: 10.1016/j.canlet.2020.10.050_bib12 article-title: Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma publication-title: J Clin Oncol. doi: 10.1200/JCO.19.03327 – volume: 21 year: 2019 ident: 10.1016/j.canlet.2020.10.050_bib102 article-title: ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM) publication-title: Neuro Oncol. doi: 10.1093/neuonc/noz175.064 – volume: 352 start-page: 997 year: 2005 ident: 10.1016/j.canlet.2020.10.050_bib41 article-title: MGMT gene silencing and benefit from temozolomide in glioblastoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa043331 – volume: 113 start-page: 259 year: 2013 ident: 10.1016/j.canlet.2020.10.050_bib7 article-title: Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution publication-title: Journal of neuro-oncology doi: 10.1007/s11060-013-1103-9 – volume: 31 start-page: 337 year: 2013 ident: 10.1016/j.canlet.2020.10.050_bib76 article-title: Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402 publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2012.43.2674 – volume: 68 start-page: 1831 year: 2007 ident: 10.1016/j.canlet.2020.10.050_bib16 article-title: Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome publication-title: Neurology doi: 10.1212/01.wnl.0000262034.26310.a2 – volume: 18 start-page: e330 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib94 article-title: European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(17)30345-5 – volume: 35 start-page: 2439 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib96 article-title: Response assessment in neuro-oncology clinical trials publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2017.72.7511 – volume: 18 start-page: 376 year: 2019 ident: 10.1016/j.canlet.2020.10.050_bib3 article-title: Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(18)30468-X – volume: 85 start-page: 329 year: 2007 ident: 10.1016/j.canlet.2020.10.050_bib87 article-title: I could lose everything: understanding the cost of a brain tumor publication-title: Journal of neuro-oncology doi: 10.1007/s11060-007-9425-0 – volume: 379 start-page: 150 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib116 article-title: Recurrent glioblastoma treated with recombinant poliovirus publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1716435 – volume: 123 start-page: 855 year: 2013 ident: 10.1016/j.canlet.2020.10.050_bib108 article-title: The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma publication-title: J. Clin. Invest. – volume: 22 start-page: 1314 year: 2016 ident: 10.1016/j.canlet.2020.10.050_bib110 article-title: Recurrent MET fusion genes represent a drug target in pediatric glioblastoma publication-title: Nat. Med. doi: 10.1038/nm.4204 – volume: 24 start-page: 4429 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib60 article-title: Machine learning-based radiomics for molecular subtyping of gliomas publication-title: Clin. Canc. Res. : an official journal of the American Association for Cancer Research doi: 10.1158/1078-0432.CCR-17-3445 – volume: 24 start-page: 1765 year: 2014 ident: 10.1016/j.canlet.2020.10.050_bib45 article-title: RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas publication-title: Genome Res. doi: 10.1101/gr.165126.113 – volume: 28 start-page: 1963 year: 2010 ident: 10.1016/j.canlet.2020.10.050_bib98 article-title: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2009.26.3541 – volume: 139 start-page: 603 year: 2020 ident: 10.1016/j.canlet.2020.10.050_bib28 article-title: cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas publication-title: Acta Neuropathol. doi: 10.1007/s00401-020-02127-9 – volume: 35 start-page: 159 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib61 article-title: A surgical strategy for lower grade gliomas using intraoperative molecular diagnosis publication-title: Brain Tumor Pathol. doi: 10.1007/s10014-018-0324-1 – volume: 337 start-page: 1231 year: 2012 ident: 10.1016/j.canlet.2020.10.050_bib43 article-title: Transforming fusions of FGFR and TACC genes in human glioblastoma publication-title: Science doi: 10.1126/science.1220834 – volume: 20 start-page: 666 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib103 article-title: A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913 publication-title: Neuro Oncol. doi: 10.1093/neuonc/nox209 – volume: 110 start-page: 156 year: 2009 ident: 10.1016/j.canlet.2020.10.050_bib70 article-title: Independent association of extent of resection with survival in patients with malignant brain astrocytoma publication-title: J. Neurosurg. doi: 10.3171/2008.4.17536 – volume: 25 start-page: 470 year: 2019 ident: 10.1016/j.canlet.2020.10.050_bib120 article-title: Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma publication-title: Nat. Med. doi: 10.1038/s41591-018-0339-5 – volume: 86 start-page: E124 year: 2020 ident: 10.1016/j.canlet.2020.10.050_bib53 article-title: A novel sequence: ZOOMit-blood oxygen level-dependent for motor-cortex localization publication-title: Neurosurgery doi: 10.1093/neuros/nyz441 – volume: 5 year: 2016 ident: 10.1016/j.canlet.2020.10.050_bib117 article-title: Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma publication-title: OncoImmunology doi: 10.1080/2162402X.2016.1196310 – volume: 38 start-page: 1990 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib54 article-title: Anatomic location of tumor predicts the accuracy of motor function localization in diffuse lower-grade gliomas involving the hand knob area publication-title: AJNR Am J Neuroradiol doi: 10.3174/ajnr.A5342 – volume: 10 start-page: 459 year: 2009 ident: 10.1016/j.canlet.2020.10.050_bib79 article-title: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(09)70025-7 – volume: 20 start-page: 1429 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib123 article-title: CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges publication-title: Neuro Oncol. doi: 10.1093/neuonc/noy032 – volume: 115 start-page: 3 year: 2011 ident: 10.1016/j.canlet.2020.10.050_bib71 article-title: An extent of resection threshold for newly diagnosed glioblastomas publication-title: J. Neurosurg. doi: 10.3171/2011.2.JNS10998 – volume: 136 start-page: 805 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib29 article-title: cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV publication-title: Acta Neuropathol. doi: 10.1007/s00401-018-1913-0 – volume: 27 start-page: 3861 year: 2009 ident: 10.1016/j.canlet.2020.10.050_bib81 article-title: Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2008.20.7944 – year: 2020 ident: 10.1016/j.canlet.2020.10.050_bib109 article-title: Clinical, molecular and radiomic profile of gliomas with FGFR3-TACC3 fusions publication-title: Neuro Oncol. doi: 10.1093/neuonc/noaa121 – volume: 23 start-page: 946 year: 2016 ident: 10.1016/j.canlet.2020.10.050_bib5 article-title: Statistical report of central nervous system tumors histologically diagnosed in the sichuan province of China from 2008 to 2013: a west China glioma center report publication-title: Ann. Surg Oncol. doi: 10.1245/s10434-016-5410-1 – volume: 26 start-page: 1586 year: 2020 ident: 10.1016/j.canlet.2020.10.050_bib37 article-title: Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial publication-title: Clin. Canc. Res. : an official journal of the American Association for Cancer Research doi: 10.1158/1078-0432.CCR-18-1140 – volume: 91 start-page: 497 year: 2015 ident: 10.1016/j.canlet.2020.10.050_bib74 article-title: Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424 publication-title: Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/j.ijrobp.2014.11.012 – volume: 9 start-page: 2554 year: 2019 ident: 10.1016/j.canlet.2020.10.050_bib122 article-title: CAR-armed cell therapy for gliomas publication-title: American journal of cancer research – volume: 22 start-page: 4797 year: 2016 ident: 10.1016/j.canlet.2020.10.050_bib104 article-title: Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082) publication-title: Clin. Canc. Res. : an official journal of the American Association for Cancer Research doi: 10.1158/1078-0432.CCR-15-3153 – volume: 129 start-page: 505 year: 2016 ident: 10.1016/j.canlet.2020.10.050_bib66 article-title: Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion publication-title: Journal of neuro-oncology doi: 10.1007/s11060-016-2201-2 – volume: 129 start-page: 1 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib67 article-title: Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI publication-title: J. Neurosurg. doi: 10.3171/2017.3.JNS162383 – volume: 23 start-page: 483 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib20 article-title: EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas publication-title: Nat. Med. doi: 10.1038/nm.4293 – volume: 45 start-page: 1141 year: 2013 ident: 10.1016/j.canlet.2020.10.050_bib111 article-title: The integrated landscape of driver genomic alterations in glioblastoma publication-title: Nat. Genet. doi: 10.1038/ng.2734 – volume: 140 start-page: 591 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib64 article-title: The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study publication-title: Journal of neuro-oncology doi: 10.1007/s11060-018-2985-3 – volume: 370 start-page: 709 year: 2014 ident: 10.1016/j.canlet.2020.10.050_bib82 article-title: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1308345 – volume: 376 start-page: 1027 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib80 article-title: Short-course radiation plus temozolomide in elderly patients with glioblastoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1611977 – volume: 53 start-page: 447 year: 2013 ident: 10.1016/j.canlet.2020.10.050_bib63 article-title: Updated therapeutic strategy for adult low-grade glioma stratified by resection and tumor subtype publication-title: Neurol. Med.-Chir. doi: 10.2176/nmc.53.447 – volume: 135 start-page: 535 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib73 article-title: The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma publication-title: Journal of neuro-oncology doi: 10.1007/s11060-017-2599-1 – volume: 18 start-page: 1373 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib113 article-title: Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(17)30517-X – volume: 129 start-page: 679 year: 2015 ident: 10.1016/j.canlet.2020.10.050_bib9 article-title: Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups publication-title: Acta Neuropathol. doi: 10.1007/s00401-015-1409-0 – volume: 15 start-page: 1148 year: 2005 ident: 10.1016/j.canlet.2020.10.050_bib50 article-title: Cortical mapping by functional magnetic resonance imaging in patients with brain tumors publication-title: Eur. Radiol. doi: 10.1007/s00330-004-2565-0 – volume: 16 start-page: 784 year: 2019 ident: 10.1016/j.canlet.2020.10.050_bib26 article-title: Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis publication-title: Cancer Biol Med doi: 10.20892/j.issn.2095-3941.2019.0143 – volume: 256 start-page: 1519 year: 2009 ident: 10.1016/j.canlet.2020.10.050_bib88 article-title: Efficacy of anti-epileptic drugs in patients with gliomas and seizures publication-title: J. Neurol. doi: 10.1007/s00415-009-5156-9 – volume: 16 start-page: 1478 year: 2014 ident: 10.1016/j.canlet.2020.10.050_bib47 article-title: Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma publication-title: Neuro Oncol. doi: 10.1093/neuonc/nou097 – volume: 8 year: 2013 ident: 10.1016/j.canlet.2020.10.050_bib52 article-title: Supratentorial gliomas in eloquent areas: which parameters can predict functional outcome and extent of resection? publication-title: PloS One doi: 10.1371/journal.pone.0080916 – volume: 140 start-page: 45 year: 2014 ident: 10.1016/j.canlet.2020.10.050_bib124 article-title: Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China publication-title: J. Canc. Res. Clin. Oncol. doi: 10.1007/s00432-013-1519-9 – volume: 136 start-page: 793 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib36 article-title: Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma publication-title: Acta Neuropathol. doi: 10.1007/s00401-018-1905-0 – volume: 74 start-page: 1886 year: 2010 ident: 10.1016/j.canlet.2020.10.050_bib15 article-title: All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 publication-title: Neurology doi: 10.1212/WNL.0b013e3181e1cf3a – volume: 100 start-page: 417 year: 2010 ident: 10.1016/j.canlet.2020.10.050_bib51 article-title: Surgical treatment of high-grade gliomas in motor areas. The impact of different supportive technologies: a 171-patient series publication-title: Journal of neuro-oncology doi: 10.1007/s11060-010-0193-x – year: 2016 ident: 10.1016/j.canlet.2020.10.050_bib19 – volume: 82 start-page: 808 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib62 article-title: The role of extent of resection in IDH1 wild-type or mutant low-grade gliomas publication-title: Neurosurgery doi: 10.1093/neuros/nyx265 – volume: 483 start-page: 479 year: 2012 ident: 10.1016/j.canlet.2020.10.050_bib11 article-title: IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype publication-title: Nature doi: 10.1038/nature10866 – volume: 22 start-page: 684 year: 2020 ident: 10.1016/j.canlet.2020.10.050_bib101 article-title: INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma publication-title: Neuro Oncol. doi: 10.1093/neuonc/noz222 – volume: 48 start-page: 768 year: 2016 ident: 10.1016/j.canlet.2020.10.050_bib112 article-title: Clonal evolution of glioblastoma under therapy publication-title: Nat. Genet. doi: 10.1038/ng.3590 – volume: 39 start-page: 1191 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib27 article-title: The clinicopathological and prognostic significance of TP53 alteration in K27M mutated gliomas: an individual-participant data meta-analysis publication-title: Neurol. Sci. doi: 10.1007/s10072-018-3407-1 – volume: 23 start-page: 493 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib21 article-title: Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas publication-title: Nat. Med. doi: 10.1038/nm.4296 – volume: 321 start-page: 1807 year: 2008 ident: 10.1016/j.canlet.2020.10.050_bib127 article-title: An integrated genomic analysis of human glioblastoma multiforme publication-title: Science doi: 10.1126/science.1164382 – volume: 27 start-page: 146 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib13 article-title: Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene Panel publication-title: Brain Pathol. doi: 10.1111/bpa.12367 – volume: 133 start-page: 1001 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib25 article-title: Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT publication-title: Acta Neuropathol. doi: 10.1007/s00401-017-1690-1 – volume: 375 start-page: 2561 year: 2016 ident: 10.1016/j.canlet.2020.10.050_bib121 article-title: Regression of glioblastoma after chimeric antigen receptor T-cell therapy publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1610497 – volume: 158 start-page: 51 year: 2016 ident: 10.1016/j.canlet.2020.10.050_bib68 article-title: Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up publication-title: Acta Neurochir. doi: 10.1007/s00701-015-2621-3 – volume: 31 start-page: 344 year: 2013 ident: 10.1016/j.canlet.2020.10.050_bib77 article-title: Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951 publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2012.43.2229 – volume: 375 start-page: 263 year: 2016 ident: 10.1016/j.canlet.2020.10.050_bib2 article-title: CGCG clinical practice guidelines for the management of adult diffuse gliomas publication-title: Canc. Lett. doi: 10.1016/j.canlet.2016.01.024 – volume: 134 start-page: 957 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib35 article-title: Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification publication-title: Acta Neuropathol. doi: 10.1007/s00401-017-1781-z – volume: 124 start-page: 2578 year: 2011 ident: 10.1016/j.canlet.2020.10.050_bib6 article-title: Prevalence estimates for primary brain tumors in China: a multi-center cross-sectional study publication-title: Chin Med J (Engl). – volume: 135 start-page: 639 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib18 article-title: cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant publication-title: Acta Neuropathol. doi: 10.1007/s00401-018-1826-y – volume: 27 start-page: 299 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib56 article-title: Post-surgical language reorganization occurs in tumors of the dominant and non-dominant hemisphere publication-title: Clin. Neuroradiol. doi: 10.1007/s00062-015-0496-6 – volume: 110 start-page: 6021 year: 2013 ident: 10.1016/j.canlet.2020.10.050_bib33 article-title: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1303607110 – volume: 12 start-page: 855 year: 2010 ident: 10.1016/j.canlet.2020.10.050_bib107 article-title: Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02) publication-title: Neuro Oncol. doi: 10.1093/neuonc/noq025 – volume: 5 start-page: 45 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib23 article-title: Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours publication-title: Acta Neuropathol Commun doi: 10.1186/s40478-017-0449-1 – volume: 18 start-page: 1529 year: 2016 ident: 10.1016/j.canlet.2020.10.050_bib17 article-title: Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide publication-title: Neuro Oncol. – volume: 21 start-page: 1519 year: 2019 ident: 10.1016/j.canlet.2020.10.050_bib31 article-title: CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas publication-title: Neuro Oncol. doi: 10.1093/neuonc/noz126.000 – volume: 10 start-page: 657 year: 2020 ident: 10.1016/j.canlet.2020.10.050_bib39 article-title: Pan-cancer efficacy of vemurafenib in BRAF (V600)-mutant non-melanoma cancers publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-19-1265 – volume: 14 start-page: iv73 issue: Suppl 4 year: 2012 ident: 10.1016/j.canlet.2020.10.050_bib93 article-title: Thromboembolic disease in patients with high-grade glioma publication-title: Neuro Oncol. doi: 10.1093/neuonc/nos197 – volume: 455 start-page: 1061 year: 2008 ident: 10.1016/j.canlet.2020.10.050_bib100 article-title: Comprehensive genomic characterization defines human glioblastoma genes and core pathways publication-title: Nature doi: 10.1038/nature07385 – volume: 54 start-page: 1886 year: 2000 ident: 10.1016/j.canlet.2020.10.050_bib91 article-title: Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology publication-title: Neurology doi: 10.1212/WNL.54.10.1886 – volume: 6 start-page: 18 year: 2020 ident: 10.1016/j.canlet.2020.10.050_bib59 article-title: Role of molecular biomarkers in glioma resection: a systematic review publication-title: Chinese Neurosurgical Journal doi: 10.1186/s41016-020-00198-x – volume: 5 start-page: 62 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib32 article-title: The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas publication-title: Acta Neuropathol Commun doi: 10.1186/s40478-017-0465-1 – volume: 70 start-page: 299 issue: 4 year: 2020 ident: 10.1016/j.canlet.2020.10.050_bib92 article-title: Management of glioblastoma: state of the art and future directions publication-title: CA Cancer J Clin. – volume: 370 start-page: 699 year: 2014 ident: 10.1016/j.canlet.2020.10.050_bib83 article-title: A randomized trial of bevacizumab for newly diagnosed glioblastoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1308573 – volume: 318 start-page: 2306 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib86 article-title: Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial publication-title: Jama doi: 10.1001/jama.2017.18718 – volume: 360 start-page: 765 year: 2009 ident: 10.1016/j.canlet.2020.10.050_bib8 article-title: IDH1 and IDH2 mutations in gliomas publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0808710 – volume: 14 start-page: 118 year: 2020 ident: 10.1016/j.canlet.2020.10.050_bib57 article-title: Motor cortical network plasticity in patients with recurrent brain tumors publication-title: Front. Hum. Neurosci. doi: 10.3389/fnhum.2020.00118 – volume: 136 start-page: 153 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib48 article-title: Novel, improved grading system(s) for IDH-mutant astrocytic gliomas publication-title: Acta Neuropathol. doi: 10.1007/s00401-018-1849-4 – volume: 13 start-page: 324 year: 2011 ident: 10.1016/j.canlet.2020.10.050_bib114 article-title: Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma publication-title: Neuro Oncol. doi: 10.1093/neuonc/noq157 – volume: 131 start-page: 803 year: 2016 ident: 10.1016/j.canlet.2020.10.050_bib1 article-title: The 2016 World Health organization classification of tumors of the central nervous system: a summary publication-title: Acta Neuropathol. doi: 10.1007/s00401-016-1545-1 – volume: 66 start-page: 115 year: 2016 ident: 10.1016/j.canlet.2020.10.050_bib4 article-title: Cancer statistics in China, 2015 publication-title: Ca - Cancer J. Clin. – volume: 148 start-page: 317 year: 2020 ident: 10.1016/j.canlet.2020.10.050_bib58 article-title: Awake craniotomy for gliomas involving motor-related areas: classification and function recovery publication-title: Journal of neuro-oncology doi: 10.1007/s11060-020-03520-w – volume: 18 start-page: 1137 year: 2016 ident: 10.1016/j.canlet.2020.10.050_bib115 article-title: Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma publication-title: Neuro Oncol. doi: 10.1093/neuonc/now002 – volume: 202 start-page: 104741 year: 2020 ident: 10.1016/j.canlet.2020.10.050_bib55 article-title: Spatiotemporal dynamics of postoperative functional plasticity in patients with brain tumors in language areas publication-title: Brain Lang. doi: 10.1016/j.bandl.2019.104741 – volume: 3 start-page: 245 year: 2016 ident: 10.1016/j.canlet.2020.10.050_bib89 article-title: Seizures and cancer: drug interactions of anticonvulsants with chemotherapeutic agents, tyrosine kinase inhibitors and glucocorticoids publication-title: Neuro-oncology practice doi: 10.1093/nop/npv038 – volume: 137 start-page: 683 year: 2019 ident: 10.1016/j.canlet.2020.10.050_bib49 article-title: cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation publication-title: Acta Neuropathol. doi: 10.1007/s00401-019-01987-0 – volume: 18 start-page: e315 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib95 article-title: European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(17)30194-8 – volume: 63 start-page: 243 year: 2017 ident: 10.1016/j.canlet.2020.10.050_bib69 article-title: Supratotal resection of diffuse gliomas - an overview of its multifaceted implications publication-title: Neurochirurgie doi: 10.1016/j.neuchi.2016.09.006 – volume: 356 start-page: 1527 year: 2007 ident: 10.1016/j.canlet.2020.10.050_bib84 article-title: Radiotherapy for glioblastoma in the elderly publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa065901 – volume: 21 start-page: 3307 year: 2015 ident: 10.1016/j.canlet.2020.10.050_bib42 article-title: Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma publication-title: Clin. Canc. Res. : an official journal of the American Association for Cancer Research doi: 10.1158/1078-0432.CCR-14-2199 – volume: 6 start-page: 495 issue: 4 year: 2020 ident: 10.1016/j.canlet.2020.10.050_bib72 article-title: Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2019.6143 – volume: 16 start-page: e534 year: 2015 ident: 10.1016/j.canlet.2020.10.050_bib99 article-title: Immunotherapy response assessment in neuro-oncology: a report of the RANO working group publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(15)00088-1 – volume: 22 start-page: 425 year: 2012 ident: 10.1016/j.canlet.2020.10.050_bib24 article-title: Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma publication-title: Canc. Cell doi: 10.1016/j.ccr.2012.08.024 – volume: 20 start-page: 66 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib30 article-title: Prognostic relevance of genetic alterations in diffuse lower-grade gliomas publication-title: Neuro Oncol. doi: 10.1093/neuonc/nox132 – volume: 30 start-page: 844 year: 2020 ident: 10.1016/j.canlet.2020.10.050_bib22 article-title: cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading publication-title: Brain Pathol. doi: 10.1111/bpa.12832 – volume: 135 start-page: 481 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib46 article-title: cIMPACT-NOW update 1: not otherwise specified (NOS) and not elsewhere classified (NEC) publication-title: Acta Neuropathol. doi: 10.1007/s00401-018-1808-0 – volume: 7 year: 2012 ident: 10.1016/j.canlet.2020.10.050_bib126 article-title: Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China publication-title: PloS One – volume: 372 start-page: 2499 year: 2015 ident: 10.1016/j.canlet.2020.10.050_bib14 article-title: Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1407279 – volume: 33 start-page: 1155 year: 2019 ident: 10.1016/j.canlet.2020.10.050_bib128 article-title: Novel IDH1-targeted glioma therapies publication-title: CNS Drugs doi: 10.1007/s40263-019-00684-6 – volume: 364 start-page: 2507 year: 2011 ident: 10.1016/j.canlet.2020.10.050_bib38 article-title: Improved survival with vemurafenib in melanoma with BRAF V600E mutation publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1103782 – volume: 99 start-page: 251 year: 2010 ident: 10.1016/j.canlet.2020.10.050_bib90 article-title: A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures publication-title: Journal of neuro-oncology doi: 10.1007/s11060-010-0126-8 – volume: 20 start-page: 110 year: 2019 ident: 10.1016/j.canlet.2020.10.050_bib105 article-title: Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(18)30675-2 – volume: 10 year: 2015 ident: 10.1016/j.canlet.2020.10.050_bib125 article-title: Isocitrate dehydrogenase 1 gene mutation is associated with prognosis in clinical low-grade gliomas publication-title: PloS One – volume: 9 start-page: 453 year: 2008 ident: 10.1016/j.canlet.2020.10.050_bib97 article-title: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(08)70125-6 – volume: 6 start-page: 1003 issue: 7 year: 2020 ident: 10.1016/j.canlet.2020.10.050_bib118 article-title: Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2020.1024 – volume: 60 start-page: 740 year: 2006 ident: 10.1016/j.canlet.2020.10.050_bib40 article-title: MGMT methylation: a marker of response to temozolomide in low-grade gliomas publication-title: Ann. Neurol. doi: 10.1002/ana.21044 – volume: 25 start-page: 477 year: 2019 ident: 10.1016/j.canlet.2020.10.050_bib119 article-title: Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma publication-title: Nat. Med. doi: 10.1038/s41591-018-0337-7 – volume: 20 start-page: 103 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib65 article-title: The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis publication-title: Neuro Oncol. doi: 10.1093/neuonc/nox176 – volume: 175 start-page: 1665 year: 2018 ident: 10.1016/j.canlet.2020.10.050_bib44 article-title: Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor publication-title: Cell doi: 10.1016/j.cell.2018.09.038 – volume: 18 start-page: 1099 year: 2016 ident: 10.1016/j.canlet.2020.10.050_bib34 article-title: Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas publication-title: Neuro Oncol. doi: 10.1093/neuonc/now021 – volume: 22 start-page: 1583 year: 2004 ident: 10.1016/j.canlet.2020.10.050_bib85 article-title: Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2004.06.082 |
| SSID | ssj0005475 |
| Score | 2.697335 |
| SecondaryResourceType | review_article |
| Snippet | To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 60 |
| SubjectTerms | Adults Brain cancer Chemoradiation Chemotherapy Chromosomes Classification Clinical medicine Clinical practice guidelines Clinical trials Diagnostic tests Glioma Histology Immune therapy Management Medical prognosis Molecular diagnostics Mutation Oncology Patients Pediatrics Radiation therapy Surgery Target therapy Tumors |
| Title | Clinical practice guidelines for the management of adult diffuse gliomas |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S030438352030584X https://dx.doi.org/10.1016/j.canlet.2020.10.050 https://www.ncbi.nlm.nih.gov/pubmed/33166616 https://www.proquest.com/docview/2473388441 https://www.proquest.com/docview/2459349873 |
| Volume | 499 |
| WOSCitedRecordID | wos000604424500010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1872-7980 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005475 issn: 0304-3835 databaseCode: AIEXJ dateStart: 19950106 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9swEBdpO8Zexr6XrSsa7K24OJZsyY-l68gGK4NlzOzFWLJcXDy7JHFo__uerA8PQmk32IsJipRIdz-fdKf7QOhDzAoB-4QKhKRhQCtZBSkJeSAqxWURV3GUmGIT7OyMZ1n6bTKpXCzMpmFty6-u0sv_ympoA2br0Nm_YLf_UWiAz8B0eALb4Xkvxp-4WEcXAHV43utcVtq_3TsV_vZeL8YRoG_WQ62UfgXdm9o7DY05DKRaHjZD7M_odFhbY_Oi6LxR2QDsYxfMr_sxysy0_trUXhR35rr_Z1EHq8Jun9b6EM3-iOYeTGJbYTEmFEtft3CTh-RIGcnKGRzlU1O2yYleaoojWeFpCgvYbdgU9NkS8MbWcAHKewtrBv0-0o1HYRyOG5p3M_yuJ6LnEWmxxmm2g_YiFqcg_faOP59mX0ZnIDqkZPYTd0GWgyfg9n_ddoi5TUkZDiuLJ-ix1TLwsUHHUzRR7TP08Kv1o3iO5g4k2IEEjyDBABIMIMEjSHBX4QEk2IIEW5C8QD8-nS5O5oGtqRFISsk6qJQsYR0zkoiUUqGLAcgCWCOSkkeF4KHQJgsWSxkWaZgSyXnBq5JRODZXoE2Sl2i37Vr1GmEl4dVOOClVDHpBPOOqKgXloHKISEmRTBFxRMqlTTiv6540ufMsvMgNaXNNWt0KpJ2iwI-6NAlX7ugfO_rnLpgYtr8cAHPHOObH2cOmOUTeY-S-Y3Nu3_tVHlFGCOdApSl6778GUa3v34pWdb3uE6eEppyRKXpl4OGXSIi-v58lb_55Wm_Ro_EF3Ue762Wv3qEHcrOuV8sDtMMyfmBhfwOmo8Jt |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+practice+guidelines+for+the+management+of+adult+diffuse+gliomas&rft.jtitle=Cancer+letters&rft.au=Jiang%2C+Tao&rft.au=Nam%2C+Do-Hyun&rft.au=Ram%2C+Zvi&rft.au=Poon%2C+Wai-sang&rft.date=2021-02-28&rft.pub=Elsevier+B.V&rft.issn=0304-3835&rft.eissn=1872-7980&rft.volume=499&rft.spage=60&rft.epage=72&rft_id=info:doi/10.1016%2Fj.canlet.2020.10.050&rft.externalDocID=S030438352030584X |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0304-3835&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0304-3835&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0304-3835&client=summon |